Project Database
Sorting
- –
- Funding ↑
- Funding ↓
- Begin ↑
- Begin ↓
- End ↑
- End ↓
- Title ↑
- Title ↓
Site
- –
- Berlin
- Extern
- Greifswald
- Göttingen
- Hamburg/Kiel/Lübeck
- Heidelberg/Mannheim
- München
- RheinMain
Project type
- –
- Daten- und Probennutzung
- Digitale Technologien
- Excellence Programme
- Ideen-Wettbewerb
- Internationale Kooperation
- Clinical Studies
- Competence Networks
- Cooperation with External Partners
- OMICs
- Shared Expertise (SE)
- Partner Site Projects
- Translational Research Project
Topic
- –
- protein based therapy
- DNA/RNA based
- Health services/health systems research
- Inflammatory heart diseases
- Mechanisms in ischemia/reperfusion
- angiogenesis
- arteriosclerosis
- cardiac hypertrophy/remodeling
- cardiomyocyte function
- endothelial cells/vascular function
- genetics of cardiovascular diseases
- iPSC
- imaging
- inflammation/vascular inflammation
- miRNAS/IncRNA
- other arrhythmias
- platelet function/thrombosis mechanisms
- stem cells/cardiac regeneration
- vascular remodelling/altering
SE Trait
- –
- SE provider
- SE user
SE Number
- –
- SE 001
- SE 004
- SE 005
- SE 006
- SE 006/SE 160
- SE 012
- SE 014
- SE 017
- SE 018
- SE 019
- SE 020
- SE 022
- SE 024
- SE 025
- SE 028
- SE 029
- SE 030
- SE 031
- SE 034
- SE 040
- SE 041
- SE 042 und SE 047
- SE 043
- SE 047
- SE 048
- SE 049
- SE 050
- SE 056
- SE 057
- SE 058
- SE 060
- SE 060/SE 080
- SE 062
- SE 063
- SE 066
- SE 067
- SE 068
- SE 078
- SE 080
- SE 081
- SE 092
- SE 094
- SE 095
- SE 097
- SE 099
- SE 100
- SE 101
- SE 102
- SE 103
- SE 104
- SE 105
- SE 106
- SE 108
- SE 109
- SE 112
- SE 113
- SE 117
- SE 118
- SE 119
- SE 120
- SE 121
- SE 122
- SE 123
- SE 124
- SE 126
- SE 127
- SE 129
- SE 131
- SE 134
- SE 136
- SE 137
- SE 138
- SE 139
- SE 140
- SE 141
- SE 144
- SE 150
- SE 152
- SE 155
- SE 157
- SE 158
- SE 159
- SE 161
- SE 163
- SE 165
- SE 166
- SE 169
- SE 170
- SE 171
- SE 173
- SE 174
- SE 177
| ID | 81X1100301 |
| Institution | Deutsches Herzzentrum Berlin |
| Project leader | Volkmar Falk |
| Site | Berlin |
| Project type | Clinical Studies |
| Funding | 2253994.00€ 2.253.994,00 |
| Begin | 2013-06-0101.06.2013 |
| End | 2023-03-3131.03.2023 |
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/
| ID | 81X1300102 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Gerd Hasenfuß |
| Site | Göttingen |
| Project type | Clinical Studies |
| Funding | 1731738.90€ 1.731.738,90 |
| Begin | 2013-08-0101.08.2013 |
| End | 2024-05-3030.05.2024 |
heart failure, asymptomatic systolic dysfunction
This cohort study explores ways of predicting when decreased cardiac performance without symptoms will develop into a clinically manifest disease. In many patients, decreased cardiac performance is detected during routine examinations without the patient showing any of the typical symptoms, such as a reduction in exercise tolerance or shortness of breath. This hidden heart failure can be caused by high blood pressure, myocardial infarction or diseases of the heart muscle. Some 1,500 such patients are to be examined and followed over a period of at least five years at the DZHK partner sites and at other clinics.
Within the scope of the study, blood markers, results from imaging studies and genetic profiles will be analysed in relation to the patients state of health and development of clinical symptoms. The emerging patterns and regularities could be used in the future to help predict when symptoms of heart failure will appear. Then therapeutic measures could be taken to counter the development of symptoms. This is all the more important because heart failure generally progresses gradually and clinicians have so far not found a way to prevent further deterioration of the condition.
| ID | 81X1300103 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Tim Friede |
| Site | Göttingen |
| Project type | Clinical Studies |
| Funding | 114959.00€ 114.959,00 |
| Begin | 2013-10-0101.10.2013 |
| End | 2022-12-3131.12.2022 |
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/
| ID | 81X1400102 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Wolfgang Hoffmann |
| Site | Greifswald |
| Project type | Clinical Studies |
| Funding | 311748.62€ 311.748,62 |
| Begin | 2013-08-0101.08.2013 |
| End | 2019-12-3131.12.2019 |
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy.
This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.
| ID | 81X1500101 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Hugo A. Katus |
| Site | Heidelberg/Mannheim |
| Project type | Clinical Studies |
| Funding | 787796.00€ 787.796,00 |
| Begin | 2013-08-0101.08.2013 |
| End | 2019-12-3131.12.2019 |
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy.
This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.
| ID | 81X1600203 |
| Institution | Klinikum der Universität München |
| Project leader | Reza Wakili |
| Site | München |
| Project type | Clinical Studies |
| Funding | 474130.00€ 474.130,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2021-06-3030.06.2021 |
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/
| ID | 81X1600501 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Adnan Kastrati |
| Site | München |
| Project type | Clinical Studies |
| Funding | 1085319.68€ 1.085.319,68 |
| Begin | 2014-08-1818.08.2014 |
| End | 2021-12-3131.12.2021 |
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year.
This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved.
The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on:
the possibility of pre-treatment independent of clinical presentation and coronary anatomy
consistently positive results in the sub-group of patients with conservative treatment strategy
potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes
To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.
| ID | 81X1600601 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Kurt Ulm |
| Site | München |
| Project type | Clinical Studies |
| Funding | 13849.14€ 13.849,14 |
| Begin | 2014-06-2727.06.2014 |
| End | 2021-10-3131.10.2021 |
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year.
This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved.
The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on:
the possibility of pre-treatment independent of clinical presentation and coronary anatomy
consistently positive results in the sub-group of patients with conservative treatment strategy
potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes
To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.
| ID | 81X1600603 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Silvia Egert |
| Site | München |
| Project type | Clinical Studies |
| Funding | 246021.00€ 246.021,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2021-06-3030.06.2021 |
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/
| ID | 81X1600701 |
| Institution | Ludwig-Maximilians-Universität München |
| Project leader | Ulrich Mansmann |
| Site | München |
| Project type | Clinical Studies |
| Funding | 54000.00€ 54.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2021-06-3030.06.2021 |
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/
| ID | 81X1700102 |
| Institution | Universität zu Lübeck |
| Project leader | Steffen Desch |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Clinical Studies |
| Funding | 1552988.84€ 1.552.988,84 |
| Begin | 2015-11-0101.11.2015 |
| End | 2022-12-3131.12.2022 |
out-of-hospital cardiac arrest, myocardial infarction, percutaneous coronary intervention
https://tomahawk.dzhk.de/
| ID | 81X2100112 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 001) |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2014-09-0101.09.2014 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100113 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Gotthardt |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 018) |
| Funding | 7000.00€ 7.000,00 |
| Begin | 2014-11-1515.11.2014 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2100115 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 15970.80€ 15.970,80 |
| Begin | 2015-02-1515.02.2015 |
| End | 2016-07-3131.07.2016 |
| ID | 81X2100116 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 001) |
| Funding | 11100.00€ 11.100,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100117 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 001) |
| Funding | 24410.00€ 24.410,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2100118 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 001) |
| Funding | 12250.00€ 12.250,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2100121 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 31428.00€ 31.428,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2100122 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Wei Chen |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 30000.00€ 30.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2100123 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2018-04-3030.04.2018 |
| ID | 81X2100124 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Wei Chen |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 55000.00€ 55.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100125 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Martin Falcke |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 014) |
| Funding | 24920.00€ 24.920,00 |
| Begin | 2015-11-1818.11.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2100126 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Natalia Alenina |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 058) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100127 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Natalia Alenina |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 139) |
| Funding | 12000.00€ 12.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100128 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Enno Klussmann |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 103) |
| Funding | 15500.00€ 15.500,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100129 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 12000.00€ 12.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2100130 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 049) |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100131 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 006) |
| Funding | 15400.00€ 15.400,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100209 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Elke Dworatzek |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 101) |
| Funding | 7280.00€ 7.280,00 |
| Begin | 2014-08-0101.08.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100212 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Karl Georg Häusler |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 078) |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2014-10-2020.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100213 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Ulrich Kintscher |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 004) |
| Funding | 12158.93€ 12.158,93 |
| Begin | 2015-01-0101.01.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100214 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Georgios Kararigas |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 034) |
| Funding | 9988.90€ 9.988,90 |
| Begin | 2015-03-0101.03.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100215 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Till Althoff |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 117) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2100216 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Georgios Kararigas |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 106) |
| Funding | 8245.33€ 8.245,33 |
| Begin | 2015-03-0101.03.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100217 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Jens Fielitz |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 14037.92€ 14.037,92 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-04-1414.04.2016 |
| ID | 81X2100218 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Wolfram Döhner |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 118) |
| Funding | 14637.36€ 14.637,36 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2100219 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Ulf Landmesser |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 097) |
| Funding | 12790.89€ 12.790,89 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2100220 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Silke Rickert-Sperling |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 019) |
| Funding | 5840.00€ 5.840,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2100221 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Till Althoff |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 112) |
| Funding | 27570.00€ 27.570,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2100222 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Antje Voigt |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 121) |
| Funding | 24978.00€ 24.978,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100223 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Mario Lorenz |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 099) |
| Funding | 9512.00€ 9.512,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100224 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Sabine Klaassen |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 136) |
| Funding | 12988.65€ 12.988,65 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2100225 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Nadja Scherbakov |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 118) |
| Funding | 13527.06€ 13.527,06 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-07-3131.07.2017 |
| ID | 81X2100226 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Philipp Jakob |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 019) |
| Funding | 14157.71€ 14.157,71 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100227 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Mario Kaßmann |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 129) |
| Funding | 11686.20€ 11.686,20 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2100228 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Silke Rickert-Sperling |
| Site | Berlin |
| Project type | Cooperation with External Partners |
| Funding | 16453.16€ 16.453,16 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100229 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Antje Voigt |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 121) |
| Funding | 29402.11€ 29.402,11 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2100230 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Sabine Klaassen |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 136) |
| Funding | 12713.94€ 12.713,94 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100231 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Antje Ludwig |
| Site | Berlin |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2100232 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Maria Luisa Barcena de Arellano |
| Site | Berlin |
| Project type | Cooperation with External Partners |
| Funding | 14992.31€ 14.992,31 |
| Begin | 2016-02-0101.02.2016 |
| End | 2017-12-3131.12.2017 |
Defining the optimal temporal and spatial resolution for cardiac magnetic resonance feature tracking
| ID | 81X2100303 |
| Institution | Deutsches Herzzentrum Berlin |
| Project leader | Sebastian Kelle |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 120) |
| Funding | 14561.20€ 14.561,20 |
| Begin | 2016-02-0101.02.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2100501 |
| Institution | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE) |
| Project leader | Matthias Schulze |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 17874.58€ 17.874,58 |
| Begin | 2014-09-1919.09.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2200108 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 097) |
| Funding | 13333.97€ 13.333,97 |
| Begin | 2014-06-0101.06.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2200112 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 042 und SE 047) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2014-09-1010.09.2014 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2200119 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 100) |
| Funding | 11000.00€ 11.000,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2200121 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 024) |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200122 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Stefanie Dimmeler |
| Site | RheinMain |
| Project type | Translational Research Project |
| Funding | 2458429.63€ 2.458.429,63 |
| Begin | 2015-02-0101.02.2015 |
| End | 2019-12-3131.12.2019 |
Based on own preliminary works that show that miR-92a inhibitors can improve cardiac function after infarction, the safety and optimisation studies necessary for an application in human beings are to be carried out in the context of the application. For this, the composition of the microRNA inhibitors is to be optimised and the necessary pharmacological and toxicological examinations are to be performed.
| ID | 81X2200126 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 097) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2200127 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 29985.26€ 29.985,26 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2200128 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 5000.00€ 5.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200129 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 137) |
| Funding | 25200.00€ 25.200,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200130 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 137) |
| Funding | 6999.16€ 6.999,16 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2200306 |
| Institution | Max-Planck-Institut für Herz- und Lungenforschung |
| Project leader | Nina Wettschureck |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 113) |
| Funding | 35130.73€ 35.130,73 |
| Begin | 2015-04-0101.04.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2200307 |
| Institution | Max-Planck-Institut für Herz- und Lungenforschung |
| Project leader | Stefan Offermanns |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 119) |
| Funding | 12840.60€ 12.840,60 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2210106 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Christoph Reinhardt |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 049) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-10-2020.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2210107 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Sven Jäckel |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 104) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2210108 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Karl Lackner |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 123) |
| Funding | 7876.79€ 7.876,79 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2210109 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Wolfram Ruf |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 121) |
| Funding | 29000.00€ 29.000,00 |
| Begin | 2015-12-0101.12.2015 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2210110 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Katrin Schäfer |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 12000.00€ 12.000,00 |
| Begin | 2015-12-0101.12.2015 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2210111 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Katrin Schäfer |
| Site | RheinMain |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 094) |
| Funding | 13500.00€ 13.500,00 |
| Begin | 2015-12-0101.12.2015 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2300111 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 019) |
| Funding | 7500.00€ 7.500,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2300112 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Kaomei Guan |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 019) |
| Funding | 15080.00€ 15.080,00 |
| Begin | 2014-10-1515.10.2014 |
| End | 2016-01-1414.01.2016 |
| ID | 81X2300114 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 017) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-10-1313.10.2014 |
| End | 2016-10-3131.10.2016 |
| ID | 81X2300116 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 078) |
| Funding | 15999.99€ 15.999,99 |
| Begin | 2014-10-1313.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2300119 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Stephan Lehnart |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 018) |
| Funding | 26321.51€ 26.321,51 |
| Begin | 2014-11-1515.11.2014 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2300122 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Katrin Streckfuß-Bömeke |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 031) |
| Funding | 9375.00€ 9.375,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2300123 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Laura Zelarayán |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 7650.00€ 7.650,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2300124 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Laura Zelarayán |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 106) |
| Funding | 22498.69€ 22.498,69 |
| Begin | 2015-01-0101.01.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2300129 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Jochen Springer |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 118) |
| Funding | 14621.54€ 14.621,54 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2300130 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Kaomei Guan |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 019) |
| Funding | 23990.66€ 23.990,66 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2300131 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Stephan Lehnart |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 7850.00€ 7.850,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2300132 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Samuel Sossalla |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 092) |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-02-2929.02.2016 |
| ID | 81X2300133 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Elisabeth Zeisberg |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 11450.00€ 11.450,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2300134 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Christoph Herrmann-Lingen |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 9550.00€ 9.550,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2300135 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Jochen Springer |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 118) |
| Funding | 13700.00€ 13.700,00 |
| Begin | 2015-07-1515.07.2015 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2300136 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Andreas Schuster |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 120) |
| Funding | 16507.04€ 16.507,04 |
| Begin | 2015-09-0101.09.2015 |
| End | 2017-01-3131.01.2017 |
| ID | 81X2300137 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Michael Didié |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 108) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2300138 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Maria Patapia Zafeiriou |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 7650.00€ 7.650,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2300139 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Ralf Dressel |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 18650.00€ 18.650,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2300140 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Samuel Sossalla |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 9000.00€ 9.000,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2300141 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Elisabeth Zeisberg |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 136) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2300142 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Jochen Springer |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 118) |
| Funding | 14332.88€ 14.332,88 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-07-3131.07.2017 |
| ID | 81X2300143 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Katrin Streckfuß-Bömeke |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 019) |
| Funding | 14442.96€ 14.442,96 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2300144 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Claudia Noack |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 15800.00€ 15.800,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2300145 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Sara Khadjeh |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 17500.00€ 17.500,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-03-3131.03.2018 |
| ID | 81X2300146 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Laura Zelarayán |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 103) |
| Funding | 13869.32€ 13.869,32 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2300147 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Katrin Streckfuß-Bömeke |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 040) |
| Funding | 15234.00€ 15.234,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2300148 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Susanne Lutz |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 094) |
| Funding | 9512.05€ 9.512,05 |
| Begin | 2015-11-0101.11.2015 |
| End | 2018-01-3131.01.2018 |
Defining the optimal temporal and spatial resolution for cardiac magnetic resonance feature tracking
| ID | 81X2300149 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Andreas Schuster |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 120) |
| Funding | 14900.00€ 14.900,00 |
| Begin | 2016-02-0101.02.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2300150 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Elisabeth Zeisberg |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 15268.29€ 15.268,29 |
| Begin | 2016-02-0101.02.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2300151 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 25774.80€ 25.774,80 |
| Begin | 2016-02-0101.02.2016 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2300401 |
| Institution | Max-Planck-Institut für Dynamik und Selbstorganisation |
| Project leader | Stefan Luther |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 048) |
| Funding | 13320.86€ 13.320,86 |
| Begin | 2015-03-1515.03.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2300402 |
| Institution | Max-Planck-Institut für Dynamik und Selbstorganisation |
| Project leader | Stefan Luther |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 014) |
| Funding | 6520.00€ 6.520,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2300403 |
| Institution | Max-Planck-Institut für Dynamik und Selbstorganisation |
| Project leader | Stefan Luther |
| Site | Göttingen |
| Project type | Translational Research Project |
| Funding | 590585.86€ 590.585,86 |
| Begin | 2016-01-0101.01.2016 |
| End | 2019-09-3030.09.2019 |
In previous studies run by the working group led by Stefan Luther it was shown that the energy applied in cardiac arrhythmias could be reduced by 80 to 90 percent compared to conventional defibrillations. In order to translate these results successfully into clinical application, the necessary proof of efficacy in an animal model is to be produced in the scope of this project: the termination of ventricular fibrillation by means of a novel defibrillator compared to conventional defibrillation will be examined in pigs used as an animal model for heart failure. The results will constitute the foundation for preparing a study for a first-in-human application.
| ID | 81X2400107 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Stephan B. Felix |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 001) |
| Funding | 8967.37€ 8.967,37 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2400108 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Bernhard Rauch |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 104) |
| Funding | 13460.00€ 13.460,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2400109 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Stephan B. Felix |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 092) |
| Funding | 11000.00€ 11.000,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2400110 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Jörg Peters |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 001) |
| Funding | 9300.78€ 9.300,78 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2400111 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Marcus Dörr |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 057) |
| Funding | 4391.44€ 4.391,44 |
| Begin | 2015-02-0101.02.2015 |
| End | 2017-01-3131.01.2017 |
| ID | 81X2400112 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Ricardo Pires |
| Site | Greifswald |
| Project type | Cooperation with External Partners |
| Funding | 19137.22€ 19.137,22 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-12-3030.12.2016 |
| ID | 81X2400113 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Sabina Ulbricht |
| Site | Greifswald |
| Project type | Cooperation with External Partners |
| Funding | 11253.80€ 11.253,80 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2400114 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Bernhard Rauch |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 104) |
| Funding | 10870.00€ 10.870,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2400115 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Jennis Freyer-Adam |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 109) |
| Funding | 4921.56€ 4.921,56 |
| Begin | 2015-07-1616.07.2015 |
| End | 2016-02-1515.02.2016 |
| ID | 81X2400116 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Alexander Teumer |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 081) |
| Funding | 14976.35€ 14.976,35 |
| Begin | 2015-07-1515.07.2015 |
| End | 2018-02-2828.02.2018 |
| ID | 81X2400118 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Uwe Völker |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 099) |
| Funding | 20080.00€ 20.080,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2400119 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Uwe Völker |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 099) |
| Funding | 20488.00€ 20.488,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2400120 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Stephanie Könemann |
| Site | Greifswald |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 102) |
| Funding | 13320.12€ 13.320,12 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2500101 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Hugo A. Katus |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) |
| Funding | 14907.52€ 14.907,52 |
| Begin | 2012-10-0808.10.2012 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2500114 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | David Hassel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 097) |
| Funding | 14628.94€ 14.628,94 |
| Begin | 2014-06-0101.06.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2500117 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Johannes Backs |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 37500.00€ 37.500,00 |
| Begin | 2014-08-1414.08.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2500118 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Mathias Konstandin |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 020) |
| Funding | 18720.91€ 18.720,91 |
| Begin | 2014-09-0404.09.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2500122 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Johannes Backs |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 019) |
| Funding | 7500.00€ 7.500,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2500125 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Benjamin Meder |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 031) |
| Funding | 12975.00€ 12.975,00 |
| Begin | 2015-04-0101.04.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2500126 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 12254.58€ 12.254,58 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2500127 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | David Hassel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 034) |
| Funding | 17715.18€ 17.715,18 |
| Begin | 2015-02-0101.02.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2500128 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Johannes Backs |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 117) |
| Funding | 14869.34€ 14.869,34 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2500129 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-02-2929.02.2016 |
| ID | 81X2500130 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Marc Freichel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 113) |
| Funding | 33955.61€ 33.955,61 |
| Begin | 2015-04-0101.04.2015 |
| End | 2016-04-0101.04.2016 |
| ID | 81X2500131 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Benjamin Meder |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 031) |
| Funding | 11475.00€ 11.475,00 |
| Begin | 2015-04-0101.04.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2500132 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Marc Freichel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 119) |
| Funding | 31416.00€ 31.416,00 |
| Begin | 2015-04-0101.04.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2500133 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Sandra Hoffmann |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 043) |
| Funding | 18491.82€ 18.491,82 |
| Begin | 2015-05-0101.05.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2500135 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Mirko Völkers |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 112) |
| Funding | 29917.66€ 29.917,66 |
| Begin | 2015-05-0101.05.2015 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2500136 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Florian Leuschner |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 121) |
| Funding | 20522.00€ 20.522,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2500137 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 022) |
| Funding | 24992.08€ 24.992,08 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2500138 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Marc Freichel |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 37492.00€ 37.492,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-07-3131.07.2016 |
| ID | 81X2500139 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | David Hassel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 034) |
| Funding | 14718.61€ 14.718,61 |
| Begin | 2015-08-0101.08.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2500140 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 13000.00€ 13.000,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2500141 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | David Hassel |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 034) |
| Funding | 19700.25€ 19.700,25 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2500142 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Benjamin Meder |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 031) |
| Funding | 23750.00€ 23.750,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2500143 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 20965.72€ 20.965,72 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2500144 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 15610.94€ 15.610,94 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2500145 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Oliver Müller |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 028) |
| Funding | 17500.00€ 17.500,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-03-3131.03.2018 |
| ID | 81X2500203 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Rudolf Schubert |
| Site | Heidelberg/Mannheim |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 129) |
| Funding | 16062.63€ 16.062,63 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-03-3131.03.2017 |
| ID | 81X2600105 |
| Institution | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Project leader | Nina Henriette Uhlenhaut |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 101) |
| Funding | 21500.00€ 21.500,00 |
| Begin | 2014-08-0101.08.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600216 |
| Institution | Klinikum der Universität München |
| Project leader | Stefan Kääb |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 8130.07€ 8.130,07 |
| Begin | 2014-10-0101.10.2014 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2600217 |
| Institution | Klinikum der Universität München |
| Project leader | Ulrich Pohl |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600218 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 105) |
| Funding | 59400.56€ 59.400,56 |
| Begin | 2014-09-1515.09.2014 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2600219 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 017) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-05-2222.05.2014 |
| End | 2016-10-3131.10.2016 |
| ID | 81X2600220 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 049) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-10-1515.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600221 |
| Institution | Klinikum der Universität München |
| Project leader | Steffen Massberg |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-09-0101.09.2014 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2600222 |
| Institution | Klinikum der Universität München |
| Project leader | Sabine Steffens |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 004) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600223 |
| Institution | Klinikum der Universität München |
| Project leader | Michael Näbauer |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 264047.60€ 264.047,60 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2600224 |
| Institution | Klinikum der Universität München |
| Project leader | Oliver Söhnlein |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2600225 |
| Institution | Klinikum der Universität München |
| Project leader | Andreas Schober |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 031) |
| Funding | 6249.99€ 6.249,99 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2600226 |
| Institution | Klinikum der Universität München |
| Project leader | Oliver Söhnlein |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2018-04-3030.04.2018 |
| ID | 81X2600227 |
| Institution | Klinikum der Universität München |
| Project leader | Ulrich Pohl |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 100) |
| Funding | 9712.44€ 9.712,44 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2600228 |
| Institution | Klinikum der Universität München |
| Project leader | Maximilian Reiser |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600229 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 049) |
| Funding | 16000.00€ 16.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600230 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 9999.00€ 9.999,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600402 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Shared Expertise (SE) |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2012-11-0101.11.2012 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600405 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 042 und SE 047) |
| Funding | 34975.54€ 34.975,54 |
| Begin | 2014-08-2121.08.2014 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2600406 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 019) |
| Funding | 14876.00€ 14.876,00 |
| Begin | 2014-10-1515.10.2014 |
| End | 2016-01-1414.01.2016 |
| ID | 81X2600408 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 108) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600409 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 9966.40€ 9.966,40 |
| Begin | 2015-12-0101.12.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2600410 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2017-05-1414.05.2017 |
| ID | 81X2600507 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Agnes Görlach |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 063) |
| Funding | 12350.00€ 12.350,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2017-08-3131.08.2017 |
| ID | 81X2600508 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 8168.48€ 8.168,48 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2600509 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 034) |
| Funding | 14590.00€ 14.590,00 |
| Begin | 2015-07-1515.07.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600510 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Andreas Petry |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 118) |
| Funding | 13700.00€ 13.700,00 |
| Begin | 2015-07-1515.07.2015 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2600511 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 081) |
| Funding | 14400.00€ 14.400,00 |
| Begin | 2015-07-1515.07.2015 |
| End | 2018-02-2828.02.2018 |
| ID | 81X2600512 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Andreas Petry |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 040) |
| Funding | 15250.00€ 15.250,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2600513 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Thorsten Kessler |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 140) |
| Funding | 18000.00€ 18.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600604 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Martin Halle |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10126.50€ 10.126,50 |
| Begin | 2014-09-0101.09.2014 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2600606 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 048) |
| Funding | 14997.92€ 14.997,92 |
| Begin | 2015-03-1515.03.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2600607 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Alessandra Moretti |
| Site | München |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 043) |
| Funding | 31485.88€ 31.485,88 |
| Begin | 2015-05-0101.05.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600608 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Alessandra Moretti |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2600609 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Translational Research Project |
| Funding | 430505.66€ 430.505,66 |
| Begin | 2016-01-0101.01.2016 |
| End | 2019-09-3030.09.2019 |
| ID | 81X2700108 |
| Institution | Universität zu Lübeck |
| Project leader | Cor de Wit |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 100) |
| Funding | 23500.00€ 23.500,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2700110 |
| Institution | Universität zu Lübeck |
| Project leader | Walter Raasch |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 001) |
| Funding | 10917.43€ 10.917,43 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700111 |
| Institution | Universität zu Lübeck |
| Project leader | Markus Schwaninger |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2015-03-0101.03.2015 |
| End | 2016-07-3131.07.2016 |
| ID | 81X2700112 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 063) |
| Funding | 10559.39€ 10.559,39 |
| Begin | 2015-05-0101.05.2015 |
| End | 2017-08-3131.08.2017 |
| ID | 81X2700113 |
| Institution | Universität zu Lübeck |
| Project leader | Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 10740.00€ 10.740,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X2700114 |
| Institution | Universität zu Lübeck |
| Project leader | Holger Thiele |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 120) |
| Funding | 16000.00€ 16.000,00 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700115 |
| Institution | Universität zu Lübeck |
| Project leader | Cor de Wit |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 100) |
| Funding | 14327.00€ 14.327,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2700116 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 058) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700117 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 139) |
| Funding | 18000.00€ 18.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700118 |
| Institution | Universität zu Lübeck |
| Project leader | Markus Schwaninger |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 3381.26€ 3.381,26 |
| Begin | 2015-12-0101.12.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2700120 |
| Institution | Universität zu Lübeck |
| Project leader | Markus Schwaninger |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 11246.12€ 11.246,12 |
| Begin | 2016-04-0101.04.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700119 |
| Institution | Universität zu Lübeck |
| Project leader | Walter Raasch |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 13800.00€ 13.800,00 |
| Begin | 2016-02-0101.02.2016 |
| End | 2018-08-3131.08.2018 |
| ID | 81X2700121 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrarhou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 140) |
| Funding | 13543.22€ 13.543,22 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2700201 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Norbert Frey |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) |
| Funding | 14551.94€ 14.551,94 |
| Begin | 2013-01-0101.01.2013 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2700206 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Derk Frank |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 001) |
| Funding | 13976.55€ 13.976,55 |
| Begin | 2014-09-2929.09.2014 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2700207 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Frey |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 022) |
| Funding | 25000.00€ 25.000,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2700208 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Derk Frank |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 034) |
| Funding | 20500.00€ 20.500,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2710107 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Thomas Eschenhagen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) |
| Funding | 9928.33€ 9.928,33 |
| Begin | 2013-11-0101.11.2013 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2710108 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Edzard Schwedhelm |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 28400.00€ 28.400,00 |
| Begin | 2014-09-0101.09.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2710109 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Thomas Eschenhagen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 020) |
| Funding | 20000.00€ 20.000,00 |
| Begin | 2014-08-2727.08.2014 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2710115 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Edzard Schwedhelm |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 104) |
| Funding | 3370.00€ 3.370,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2710116 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Arne Hansen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 024) |
| Funding | 15727.99€ 15.727,99 |
| Begin | 2015-03-0101.03.2015 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2710117 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Dirk Westermann |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 092) |
| Funding | 21000.04€ 21.000,04 |
| Begin | 2015-02-0101.02.2015 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2710121 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Edzard Schwedhelm |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 057) |
| Funding | 30000.00€ 30.000,00 |
| Begin | 2015-02-0101.02.2015 |
| End | 2017-01-3131.01.2017 |
| ID | 81X2710124 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Dirk Westermann |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 092) |
| Funding | 16000.00€ 16.000,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-02-2929.02.2016 |
| ID | 81X2710125 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Lucie Carrier |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 006) |
| Funding | 7857.00€ 7.857,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2710126 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Birgit-Christiane Zyriax |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 109) |
| Funding | 5000.00€ 5.000,00 |
| Begin | 2015-07-1616.07.2015 |
| End | 2016-02-1515.02.2016 |
| ID | 81X2710127 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Lucie Carrier |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2710129 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Tanja Zeller |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 099) |
| Funding | 9966.64€ 9.966,64 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2710130 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Mahir Karakas |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 123) |
| Funding | 2000.00€ 2.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2710131 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Elke Oetjen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 4614.00€ 4.614,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2710132 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Sonja Schrepfer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2710133 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Viacheslav Nicolaev |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 028) |
| Funding | 5260.00€ 5.260,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2710134 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Friederike Cuello |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 137) |
| Funding | 10200.00€ 10.200,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2710135 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Giulia Mearini |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 136) |
| Funding | 17991.36€ 17.991,36 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2710136 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Lucie Carrier |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 102) |
| Funding | 19033.78€ 19.033,78 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2710137 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Friederike Cuello |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 137) |
| Funding | 3000.00€ 3.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800105 |
| Institution | Albert-Ludwigs-Universität Freiburg |
| Project leader | Lutz Hein |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 41667.00€ 41.667,00 |
| Begin | 2014-09-1616.09.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800106 |
| Institution | Ruhr-Universität Bochum Universitätsklinik Herz- und Diabeteszentrum Nordrhein-Westfalen |
| Project leader | Hendrik Milting |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-10-0101.10.2014 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800108 |
| Institution | Universitätsklinikum Essen |
| Project leader | Dobromir Dobrev |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10990.00€ 10.990,00 |
| Begin | 2014-11-1313.11.2014 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2800109 |
| Institution | Eberhard Karls Universität Tübingen |
| Project leader | Karin Klingel |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 32640.82€ 32.640,82 |
| Begin | 2014-10-0101.10.2014 |
| End | 2017-01-3131.01.2017 |
| ID | 81X2800110 |
| Institution | Kompetenznetz Vorhofflimmern e. V. |
| Project leader | Günter Breithardt |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 1334538.96€ 1.334.538,96 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800111 |
| Institution | Nationales Register für angeborene Herzfehler e.V. |
| Project leader | Ulrike Bauer |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 3213770.56€ 3.213.770,56 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800112 |
| Institution | Kompetenznetz Angeborene Herzfehler e. V. |
| Project leader | Ulrike Bauer |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 754578.72€ 754.578,72 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800113 |
| Institution | Universitätsklinikum Würzburg |
| Project leader | Stefan Störk |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 873277.56€ 873.277,56 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800114 |
| Institution | Universitätsklinikum Ulm |
| Project leader | Wolfgang Koenig |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 9796.80€ 9.796,80 |
| Begin | 2014-12-0101.12.2014 |
| End | 2016-03-3131.03.2016 |
| ID | 81X2800115 |
| Institution | Eberhard Karls Universität Tübingen |
| Project leader | Tobias Geisler |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2014-11-0101.11.2014 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2800117 |
| Institution | Heinrich-Heine-Universität Düsseldorf |
| Project leader | Friedrich Boege |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 23500.00€ 23.500,00 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-12-3030.12.2016 |
| ID | 81X2800118 |
| Institution | Westfälische Wilhelms-Universität Münster |
| Project leader | Alexander Zarbock |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 9692.43€ 9.692,43 |
| Begin | 2015-05-0101.05.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2800119 |
| Institution | Universität Leipzig |
| Project leader | Markus Löffler |
| Site | Extern |
| Project type | Competence Networks |
| Funding | 567036.88€ 567.036,88 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800120 |
| Institution | Universität Bielefeld |
| Project leader | Michael Schwake |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 18000.00€ 18.000,00 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2800121 |
| Institution | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| Project leader | Susanne Wurm |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 12605.04€ 12.605,04 |
| Begin | 2015-06-0101.06.2015 |
| End | 2016-01-3131.01.2016 |
| ID | 81X2800122 |
| Institution | Universität Potsdam |
| Project leader | Salim Seyfried |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10740.00€ 10.740,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2800123 |
| Institution | Medizinische Hochschule Hannover - Zentrum Innere Medizin - Klinik für Nieren- und Hochdruckerkrankungen |
| Project leader | Sibylle von Vietinghoff |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14450.00€ 14.450,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2800124 |
| Institution | Philipps-Universität Marburg |
| Project leader | Ralph T. Schwarz |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10250.02€ 10.250,02 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2800125 |
| Institution | Albert-Ludwigs-Universität Freiburg |
| Project leader | Lutz Hein |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 9900.00€ 9.900,00 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-04-3030.04.2016 |
| ID | 81X2800126 |
| Institution | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
| Project leader | Ole Pleß |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 16000.00€ 16.000,00 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-06-3030.06.2016 |
| ID | 81X2800127 |
| Institution | Universität des Saarlandes |
| Project leader | Peter Lipp |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 9800.00€ 9.800,00 |
| Begin | 2015-09-0101.09.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X2800128 |
| Institution | Universität des Saarlandes |
| Project leader | Peter Lipp |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 37502.00€ 37.502,00 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-07-3131.07.2016 |
| ID | 81X2800129 |
| Institution | Universitätsklinikum Tübingen |
| Project leader | Mike Notohamiprodjo |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 8688.90€ 8.688,90 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800130 |
| Institution | Medizinische Hochschule Hannover |
| Project leader | Thomas Thum |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-07-3030.07.2016 |
| ID | 81X2800131 |
| Institution | Universität zu Köln |
| Project leader | Elke Oetjen |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 7149.98€ 7.149,98 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800132 |
| Institution | Universität zu Köln |
| Project leader | Matti Adam |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 9880.27€ 9.880,27 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800133 |
| Institution | Heinrich-Heine-Universität Düsseldorf |
| Project leader | Markus Uhrberg |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2800134 |
| Institution | Technische Universität Dresden |
| Project leader | Ali El-Armouche |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 13999.99€ 13.999,99 |
| Begin | 2015-11-0101.11.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X2800135 |
| Institution | Medizinische Hochschule Hannover |
| Project leader | Thomas Thum |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2017-05-1414.05.2017 |
| ID | 81X2800136 |
| Institution | Universitätsklinikum Essen |
| Project leader | Dobromir Dobrev |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800137 |
| Institution | Medizinisches Laserzentrum Lübeck GmbH |
| Project leader | Gereon Hüttmann |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15975.00€ 15.975,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-05-3131.05.2016 |
| ID | 81X2800139 |
| Institution | Albert-Ludwigs-Universität Freiburg - Medizinische Fakultät |
| Project leader | Andreas Zirlik |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800140 |
| Institution | Justus-Liebig-Universität Gießen |
| Project leader | Dursun Gündüz |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 13550.74€ 13.550,74 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800141 |
| Institution | Hochschule Darmstadt |
| Project leader | Ralf Blendowske |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 5200.00€ 5.200,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2016-09-3030.09.2016 |
| ID | 81X3100202 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Nadine Althof |
| Site | Berlin |
| Project type | Excellence Programme |
| Funding | 30761.12€ 30.761,12 |
| Begin | 2015-07-0101.07.2015 |
| End | 2017-06-2121.06.2017 |
| ID | 81X3100302 |
| Institution | Deutsches Herzzentrum Berlin |
| Project leader | Nadya Al-Wakeel |
| Site | Berlin |
| Project type | Excellence Programme |
| Funding | 85635.56€ 85.635,56 |
| Begin | 2015-08-0101.08.2015 |
| End | 2018-09-3030.09.2018 |
| ID | 81X3200301 |
| Institution | Max-Planck-Institut für Herz- und Lungenforschung |
| Project leader | Holger Lörchner |
| Site | RheinMain |
| Project type | Excellence Programme |
| Funding | 58624.31€ 58.624,31 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-11-3030.11.2016 |
| ID | 81X3200302 |
| Institution | Max-Planck-Institut für Herz- und Lungenforschung |
| Project leader | Ryota Matsuoka |
| Site | RheinMain |
| Project type | Excellence Programme |
| Funding | 60000.00€ 60.000,00 |
| Begin | 2015-10-0101.10.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X3500106 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Maura Magdalena Zylla |
| Site | Heidelberg/Mannheim |
| Project type | Excellence Programme |
| Funding | 86900.00€ 86.900,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-12-3131.12.2016 |
| ID | 81X3500108 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Lisa Tilemann |
| Site | Heidelberg/Mannheim |
| Project type | Excellence Programme |
| Funding | 76778.00€ 76.778,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X3600203 |
| Institution | Klinikum der Universität München |
| Project leader | Maliheh Nazari-Jahantigh |
| Site | München |
| Project type | Excellence Programme |
| Funding | 60000.00€ 60.000,00 |
| Begin | 2015-12-0101.12.2015 |
| End | 2017-03-3131.03.2017 |
| ID | 81X3600502 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Thorsten Kessler |
| Site | München |
| Project type | Excellence Programme |
| Funding | 94000.00€ 94.000,00 |
| Begin | 2015-07-0101.07.2015 |
| End | 2016-09-3030.09.2016 |
| ID | 81X3700202 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Constantin Kühl |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Excellence Programme |
| Funding | 94000.00€ 94.000,00 |
| Begin | 2015-08-0101.08.2015 |
| End | 2016-08-3131.08.2016 |
| ID | 81X3710105 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Michael Schwarzl |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Excellence Programme |
| Funding | 89800.00€ 89.800,00 |
| Begin | 2015-11-0101.11.2015 |
| End | 2017-01-3131.01.2017 |
| ID | 81Z1100101 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Dominik Müller |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | inflammation/vascular inflammation |
| Funding | 268000.00€ 268.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
microbiome, CVD
The microbiome includes a diverse community of bacteria in our gut and its impact on health has spawned the Human Microbiome Project. This immensely rich bacterial community, which is known to respond to fluctuations in lifestyle and diet, is increasingly recognized as an important factor that influences host health and disease. Several diseases have been shown to be influenced by gut microbiota, such as obesity, diabetes mellitus, inflammatory bowel disease and autoimmune disease. Even though the importance of the gut microbiome has been recognized, the role of environmental factors like high salt on the gut microbiome as well as the role for the gut microbiota in hypertension-induced target organ damage is not known. The project addresses these isuues.
| ID | 81Z1100102 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Sebastian Diecke |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | iPSC |
| Funding | 717760.92€ 717.760,92 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Stem cells, Genome editing, differentiation, reprogramming, disease modeling, screening
The Stem Cell platform of the DZHK in Berlin was established to provide stem cell specific services to scientists of the DZHK to overcome technical obstacles in a field of reprogramming, differentiation and genome editing rapidly growing and full of spectacular innovations.The stem cell platform already established feeder free cultivation system of hiPSC using homemade chemical defined media and different endothelial and cardiac, differentiation protocols in cooperation with the DZHK affiliated groups of Prof. Willnow, Hübner, Sperling, Gerhardt. The stem cell platform also performed genome engineering experiments using Crispr/Cas9 or TALEN mediated gene targeting and derived different disease and non- disease specific patient iPSC lines using different reprogramming techniques.
| ID | 81Z1100103 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Tobias Pischon |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | arteriosclerosis |
| Funding | 258000.00€ 258.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
myocardial infarction, diet, nutrition, physical activity, patients
Current guidelines recommend a healthy diet and physical activity of at least moderate intensity for management of cardiovascular risk. Recent studies suggest that a Mediterranean diet reduces the risk of major cardiovascular events among persons at high cardiovascular risk. However, it is unclear whether in non-Mediterranean countries, diets similar to the Mediterranean diet have comparable effects. Further, preliminary evidence indicates that interval-based vigorous physical activity may be at least as beneficial as moderate activity. The aim of this project is therefore to study in a German population the association of diet, physical activity, lifestyle, and metabolic factors with prognosis of patients with history of myocardial infarction.
| ID | 81Z1100104 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Holger Gerhardt |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | vascular remodelling/altering |
| Funding | 2358269.00€ 2.358.269,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
angiogenesis, imaging, blood flow, mouse, zebrafish
Our recent work on endothelial cell specification, competition, dynamic rearrangements, Notch signalling synchronization, and vessel regression established key principles in vascular patterning and malformations. Challenges ahead lie in the multiscale and multiphysics nature of vascular remodelling. Our project bridges across scales and disciplines to establish mechanisms of dynamic cell polarity establishment and regulation of endothelial cell shape in vascular remodelling, as well as transmission and integration of physical forces with signalling to influence shape and polarity of individual cells. We then ask how collective cell behaviour under the influence of the above-mentioned principles is coordinated with blood flow and tissue responses to achieve functional remodelling.
| ID | 81Z1100112 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Nikolaus Rajewski |
| Site | Berlin |
| Project type | Partner Site Projects |
| Funding | 336060.00€ 336.060,00 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z1100201 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Ulrich Dirnagl |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | angiogenesis |
| Funding | 473143.09€ 473.143,09 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Ischemic stroke is a vascular disease affecting neuronal function. The bimodal response of the neurovascular unit (NVU) to brain ischemia is characterized by an early blood-brain-barrier disruption followed later by vascular remodelling and, hence, a switch from brain injury to repair and recovery. The aim of this project is to target extracellular matrix (ECM) components essential for NVU integrity to protect from stroke and to identify novel biomarkers to translate these findings into clinical practice. Using a model of transient focal brain ischemia and a genetically modified mice, we investigate the role of key ECM components for stroke outcome and their potential use as biomarkers for the switch from injury to recovery.
| ID | 81Z1200101 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Stefanie Dimmeler |
| Site | RheinMain |
| Project type | Partner Site Projects | Topic | miRNAS/IncRNA |
| Funding | 1404260.50€ 1.404.260,50 |
| Begin | 2014-09-1010.09.2014 |
| End | 2018-12-3131.12.2018 |
cardiovascular, RNA, miRNA, lncRNA, RNA therapeutics
In the last years, it has become evident that the majority of the genome is transcribed, while only about 2% codes for proteins. These so-called non-coding RNAs (ncRNAs) comprise microRNAs, long ncRNAs (>200 nt) and circular RNAs (circRNAs). The research groups of Prof. Dimmeler, Prof. Fleming and Prof. Brandes at RheinMain have extensive expertise in non-coding RNA research including the development of microRNA inhibitors in angiogenesis, cardiac aging and aneurysm formation as well as the characterization of the long non-coding RNAs in endothelial cell functions in vitro and in vivo. In frame of this common project we will join efforts to better understand the function of lncRNAs and circRNAs in the cardiovascular system in order to identify putative novel therapeutic targets.
| ID | 81Z1200102 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Partner Site Projects | Topic | stem cells/cardiac regeneration |
| Funding | 239999.80€ 239.999,80 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
acute myocardial infarction, heart failure, stem cell therapy
Intracoronary therapy using autologous bone-marrow derived cells (BMCs) has been shown to moderately improve left ventricular function in patients with acute myocardial infarction and chronic heart failure. One of the key factors influencing the efficacy of the application is certainly the heterogeneity of the cell products which varies depending on the genetic determinants and risk factors of the individual patients. Focus of this project is the establishment of fast and easy-to-perform in vitro methods to analyze the functionality of BMCs already before the re-application in the patient. Identification of factors determining the functionality of the applied cellular product might also enable ex-vivo modification by drugs or small molecules in order to further enhance the efficacy of cell therapy in patients with cardiovascular diseases.
| ID | 81Z1200201 |
| Institution | Kerckhoff-Klinik, Gesellschaft mit beschränkter Haftung |
| Project leader | Christian Hamm |
| Site | RheinMain |
| Project type | Partner Site Projects |
| Funding | 921948.23€ 921.948,23 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
biomarker, heart failure, microRNA
The Biomarker Research Group aims to identify and validate of cardiac biomarkers, which is the central area of clinical and basic research in this Project in order to improve diagnosis, decision on therapeutic strategies and prognosis of cardiovascular disease. Only a few Biomarkers (e.g. Troponin, CKMB) have made into daily clinical practice and are routinely measured in patients in a limited number of clinical settings (exclusion of myocardial infarction). Thus, there is an essential need for a broader range of biomarkers not only in the context of myocardial infarction but also for other cardiac and vascular diseases like heart failure (diastolic/systolic dysfunction), right/left ventricular insufficiency and for cardiac ischemia. Furthermore, new concepts of (bio)-markers (e.g. circulating micro-RNAs and molecular signature of circulating mononuclear cells) are investigated for their potential to act as therapeutic or prognostic indicators of cardiac pathologies.
| ID | 81Z1400101 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Raila Busch |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | endothelial cells/vascular function |
| Funding | 560749.31€ 560.749,31 |
| Begin | 2014-08-1818.08.2014 |
| End | 2018-12-3131.12.2018 |
exercise, lipid-lowering medication, interactive effects, endothelial function, animal models, cell culture and flow-chamber experiments
This project investigates the interaction between pharmacological therapies and life-style changes as non-pharmacological intervention. The current guidelines recommend a combination of pharmacological and non-pharmacological approaches. However, little is known at the current state e.g. how life-style interventions like exercise training and medication interact. For primary and secondary prevention interactions between exercise training and lipid lowering medication is of high interest. Up to now it is still unclear if the positive effects of exercise training or lipid lowering medication alone act additively/synergisticly or counteractively when applied in combination as recommended by the guidelines. The major aim of this project is to investigate the effects of lipid lowering medication on endothelial/vascular function in cell culture models. Furthermore animal models shall provide insights into the interaction of exercise training and lipid lowering medication on cardiopulmonary capacity, vascular and heart function.
| ID | 81Z1600211 |
| Institution | Klinikum der Universität München |
| Project leader | Ulrich Pohl |
| Site | München |
| Project type | Partner Site Projects | Topic | vascular remodelling/altering |
| Funding | 718832.52€ 718.832,52 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
smooth muscle, AMPK, connexins, cell migration, cytoskelton, podosomes, mitochnodrial impairment
In this project we study the role of vascular connexins in remodelling processes. Using genetic connexin mutations their effect on of vascular on cell growth and migration and heterocellular communication are analyzed. We further study the role endothelial mitochondrial impairment, cytoskeletal reorganization and altered smooth muscle calcium homeostasis on cellular migration in isolated cultured microvessels and a model of arteriogenesis. One of the targets is the AMP-activated kinase (AMPK) which establishes a close link to metabolic and inflammatory diseases and microvascular remodelling
| ID | 81Z1600212 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Partner Site Projects | Topic | inflammation/vascular inflammation |
| Funding | 1849181.03€ 1.849.181,03 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
chemokine, heteromer, neutrophil, platelet, inflammation, recruitment
The newly established research group headed by the DZHK-Professor Oliver Soehnlein shall develop and pursue novel concepts for target identification and therapeutic exploitation in the context of the chemokine-interactome, leukocytic granule proteins, and costimulatory molecules for the treatment of inflammatory aspects of cardiovascular diseases. These are based on detailed structure-function analyses, modelling of molecular interactions, and synthetic peptide chemistry for generation of interceptors, which shall be validated and optimized for safety and efficacy during atherogenic immune cell recruitment. It is the aim to generate peptides for use in clinical studies which shall be realized in subsequent funding periods.
| ID | 81Z1600214 |
| Institution | Klinikum der Universität München |
| Project leader | Steffen Massberg |
| Site | München |
| Project type | Partner Site Projects | Topic | platelet function/thrombosis mechanisms |
| Funding | 1567485.72€ 1.567.485,72 |
| Begin | 2013-05-0101.05.2013 |
| End | 2018-12-3131.12.2018 |
platelet, thrombosis, immune cells, coagulation
Platelets are central mediators of arterial thrombosis and the main target of treatment as well as prophylaxis of coronary heart disease. However, despite improvements in antiplatelet therapy thrombotic disorders a still a leading cause of mortality worldwide. Therefore, the central aim of this project is to pave the way for innovative therapeutic approaches targeting the prothrombotic functions of platelets. This is based on an improved understanding of the interactions of platelets with the coagulation as well as the immune system using state-of-the-art basic science approaches and reaching to clinical evaluation. The results of this project will provide valuable insight into the mechanisms of thrombotic disorders and will break new ground for the treatment of coronary heart disease.
| ID | 81Z1600215 |
| Institution | Klinikum der Universität München |
| Project leader | Julinda Mehilli |
| Site | München |
| Project type | Partner Site Projects |
| Funding | 581646.43€ 581.646,43 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
gender, women, TAVI, TAVR, AS,HTx, heart transplantation,CAD, BRS, scaffold
gender-related analyses from different registries and ongoing randomized trials focused on clinical outcomes after trans-catheter aortic valve repair, after heart transplantation as well as after implantation of bioresorbable vascular scaffolds
| ID | 81Z1600313 |
| Institution | Max-Planck-Institut für Biochemie |
| Project leader | Reinhard Fässler |
| Site | München |
| Project type | Partner Site Projects | Topic | endothelial cells/vascular function |
| Funding | 775111.00€ 775.111,00 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
cell adhesion signaling, knock-out mice, parvin, integrin, cardiomyocytes, vascular smooth muscle cells, hypertrophy, proteomics
The project cell adhesion in coronary heart diseases makes use of genetically modified mouse lines to analyze the role of integrin-mediated adhesion of vascular smooth muscle cell and cardiomyocyte to the extracellular matrix (cell-matrix adhesion) and neighboring cells (cell-cell adhesion) in vivo. We aim to characterize ?-Parvin and ?-Parvin-regulated signal pathways that control vascular and cardiomyocyte function and the progression of CHDs (such as aneurysms, hypertonia or hypertrophy) by a combination of genetic experiments in mice, cell biology and proteomic analysis. A second aim is the development of therapeutic strategies for the treatment of CHDs using synthetic peptides that bind to and inactivate cell adhesion proteins.
| ID | 81Z1600512 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 831297.87€ 831.297,87 |
| Begin | 2013-01-0101.01.2013 |
| End | 2018-12-3131.12.2018 |
animal models, genome-wide association studies, coronary artery disease, myocardial infarction
Our group has significantly contributed to the discovery and functional analysis of a large number of genomic variants which were identified to be genome-wide significantly associated with coronary artery disease. Hence, several transgenic animal models as well as novel bioinformatics strategies have been established to enable the analysis of networks and signaling pathways. In the project Experimental and integrative analysis of CAD we aim to experimentally explore these tools of functional gene analysis. Furthermore, using OMICS datasets and animal models, which are based on the genome-wide significant coronary artery disease loci, we aim to improve the understanding of the molecular consequences of the identified variants for the development of coronary artery disease and myocardial infarction.
| ID | 81Z1600514 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Adnan Kastrati |
| Site | München |
| Project type | Partner Site Projects |
| Funding | 1308270.36€ 1.308.270,36 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
Coronary artery disease, thrombosis, restenosis, platelet, aggregation, stent, women,antiproliferative drug, antiplatelet drug, clinical trial, phase II
The objective is 2 fold: evaluation of new therapeutic concepts for the prevention of stent thrombosis and restenosis. A new substance, a glycoproten VI inhibitor, Revacept, which prevents the adhesion of platelets to the vessel wall injury site, is expected to protect against thrombosis without impacting significantly on bleeding. Preclinical and phase I studies have shown promise that Revacept might be an effective and safe drug for prevention of thrombotic events after percutaneous coronary intervention. This substance will be assessed in a phase II clinical trial. The second objective is the development of safer and effective drug-eluting stents. RGD peptide and novel fully resorbable polymers will be subject of pre-clinical and first-in-man studies. We are establishing an early clinical trial unit for the conductance of these studies.
| ID | 81Z1700101 |
| Institution | Universität zu Lübeck |
| Project leader | Jeanette Erdmann |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 1841521.35€ 1.841.521,35 |
| Begin | 2014-11-0505.11.2014 |
| End | 2018-12-3131.12.2018 |
myocardial infarction, coronary artery disease, genetics, GWAS, animal models, SNPs, NGS
The project aims to systematically explore the human genome in cardiovascular disease, as well as to study the functional consequences of genomic variations in human cell and animal models. We wish to enhance diagnostic and therapeutic options particularly in the context of atherosclerosis and myocardial infarction. We systematically explored genome-wide association as well as genome-wide sequencing data and contributed to the identification of most currently known alleles affecting risk of the disease. Transgenic animal models (mice), also based on these newly identified genes, are about to further refine the mechanistic understanding of these processes. We aim to utilize these resources for the benefit of patients in terms of improved risk prediction and individualized medical treatment.
| ID | 81Z1700102 |
| Institution | Universität zu Lübeck |
| Project leader | Cor de Wit |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 324845.45€ 324.845,45 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
endothelium, microcirculation, knockout-models
This project is aimed to analyse mouse models that carry identified CAD/MI genes with respect to flow regulation in the microcirculation, neointima formation in carotid artery, and platelet aggregation in arterioles. Flow regulation is studied by measuring arteriolar diameter changes in the in vivo setting before and after stimulation using vasoactive agents. Neointima formation is an in vivo model of atherosclerosis that induces a switch in smooth muscle phenotype. Thrombus formation is initiated in vivo in arterioles by mechanical or excitation of light-sensitive dyes to induce platelet activation. By these means we aim to obtain insight into pathophysiological mechanisms that are initiated by such genes of risk which ultimately may cause or promote CAD/MI.
| ID | 81Z1700103 |
| Institution | Universität zu Lübeck |
| Project leader | Inke R. König |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 165000.00€ 165.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
biomarker, simulation, interaction, study design, randomise all, biomarker stratified, subgroup analysis
The first aim is to derive practical recommendations for identifying interactions between predictive biomarkers and treatments in different study designs via simulations based on distinct regression models. The first step is to design simulation scenarios based on effects and effect combinations described in literature. Next, transformations are developed to define equivalent effects in different regression models resulting in subsequent simulation runs. The second aim is to give recommendations how to analyse subgroup designs defined by multiple biomarkers. The first step here is again to design simulation scenarios by literature search. Practical recommendations arise from simulations based on these scenarios, and unbiased estimators for treatment and biomarker effects will be developed.
| ID | 81Z1700104 |
| Institution | Universität zu Lübeck |
| Project leader | Frank Kaiser |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 190000.00€ 190.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
chromatin, SNP, transcription, mutation
To characterize genetic variants associated with cardiovascular disease two different analytic pipelines are used. The first one is focusing on variants affecting protein coding regions of the genome by a broad spectrum of different technologies (two hybrid assays, immunoprecipitation or ChIP) to investigate exchanges of selected amino acids on protein complex formation or protein DNA interaction. The second part of this project is focusing on variants within the non-coding part of the genome. Based on public or own databases variants are rated and listed regarding their predicted functional relevance. Selected variants will be analyzed by cellular in-vitro systems and chromatin conformation capture assays to investigate their effect on chromatin structure and gene expression.
| ID | 81Z1700105 |
| Institution | Universität zu Lübeck |
| Project leader | Markus Schwaninger |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | endothelial cells/vascular function |
| Funding | 250009.05€ 250.009,05 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
optical coherence tomography, diabetic complications, diabetic microvascular pathology, incontinentia pigmenti, small vessel diseases, NF-kB, gene therapy
Our project investigates vascular pruning and remodeling in mouse models of disease. We focus on (i) diabetes and (ii) incontinentia pigmenti, a genetic disease that leads to vascular pathology in the brain. Although diverse in etiology, the two conditions share an involvement of the proinflammatory transcription factor NF-?B. To explore whether interfering with NF-?B signaling offers therapeutic opportunities, we employ classical small-molecule pharmacology as well as gene therapy approaches. Optical coherence tomography and various physiological or morphological techniques are used to evaluate the vasculature.
| ID | 81Z1710101 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Tanja Zeller |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 1368872.73€ 1.368.872,73 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
OMICS, cardiovascular genetics, genomics, gene expression, candidate genes, translation, clinical application, systems medicine
Systems medince approaches to characterize candidate genes and networks of cardiovascular diseases such as myocardial infarction, heart failure and atrial fibrillation. As resources we use large-scale omics and phenotypic data sets as well as comprehensive biobanks of population-based and disease cohorts. Candidate genes are investigated at the molecular and cellular levels. Findings are translated into clinical disease models and tested for clinical application.
| ID | 81Z1710102 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Edzard Schwedhelm |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects |
| Funding | 368000.00€ 368.000,00 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
AGAT, CRTC1, homoarginine
L-arginine:glycine amidinotransferase (AGAT) is involved in creatine as well as homoarginine (hArg) synthesis. hArg is an amino acid identified as risk marker in cardiovascular (CV) and cerebrovascular diseases. Cardiac phenotyping of AGAT deficient, Mybpc3-targeted knock-in, and CREB-regulated transcription coactivator 1 deficient mice is part of the project for a better understanding of processes in CV diseases. The aim of the project is to investigate the potential relevance of the AGAT/hArg pathway as a new therapeutic approach in CV diseases, e.g. atrial fibrillation, stroke/transient ischemic attack, heart failure, and hypertrophic cardiomyopathy with AGAT modulators, identified by high throughput screening, and homoarginine supplementation in healthy and diseased patients.
| ID | 81Z1710103 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Renate B. Schnabel |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | other arrhythmias |
| Funding | 208086.86€ 208.086,86 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
atrial fibrillation, risk prediction, outcome, epidemiology
At University Heart Centre Hamburg we have established obserational cohorts to investigate incidence and outcome of atrial fibrillation. Cohorts range from population-based individuals to patients at risk of developing atrial fibrillation, lone atrial fibrillation, and postoperative new-onset disease. In the DZHK project we perform epidemiological analyses that examine classical risk factors and novel risk markers for atrial fibrillation. Our aim is to improve the understanding of the disease pathophysiology and its natural history. In pre-defined subgroups we try to improve risk prediction beyond existing risk algorithms. In addition, by our well-characterized cohorts we provide a clinical-epidemiological basis for a fast translation of basic research findings into the clinical setting.
| ID | 81Z2100101 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Norbert Hübner |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 193415.05€ 193.415,05 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Genetic variation, transcriptional and translational regulation
We investigate the molecular basis of cardiovascular diseases with a main focus on dilated cardiomyopathy (DCM), a major cause of congestive heart failure. Genetic factors are known to play an important role in disease etiology but the molecular mechanisms are largely unknown.
In order to elucidate the impact of pathogenic variation, we perform RNA-seq and ribosome profiling of cardiac disease tissue. Ribosome profiling is a powerful and novel methodology to obtain qualitative and quantitative information about translation on a genome-wide scale. This technology provides a way to thoroughly investigate translational regulation and to significantly improve the estimate of protein levels compared to traditional gene expression approaches.
| ID | 81Z2100102 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Gotthardt |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | cardiomyocyte function |
| Funding | 361000.00€ 361.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
RNA, splicing, therapy
The project alternative splicing as a therapeutic target for cardiac diseases builds on our identification of RBM20 as a splice factor with substrates related to sarcomere function and calcium homeostasis. We will study the regulation of RBM20 expression and function, as well as its interaction with other proteins to identify potential therapeutic targets. Through the coordinated interference with cardiac isoform expression, we will adapt the elastic and electrical properties of the heart.
| ID | 81Z2100201 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Vera Regitz-Zagrosek |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 931131.01€ 931.131,01 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
calcium, fibrosis, hormone, mitochondria, receptor
There are major sex differences in heart failure. The overall hypothesis is that female sex or sex hormones lead to better maintenance of mitochondrial function, calcium handling and reduced fibrosis and apoptosis under stress. To investigate these processes, we use animal models and tissues from male and female patients undergoing cardiac surgery in the following objectives: 1) sex-specific role of ER? and ER? on mitochondrial energy production in the human heart; 2) sex-specific role of ER? and ER? effects in cardiac fibrosis; 3) role of mitochondrial cAMP-signaling in the cardioprotective effects of ER; 4) sex differences in calcium-dependent cardiomyocyte death in heart failure; 5) integrative model of sex differences in cardiomyocyte function and testing of targets.
| ID | 81Z2100202 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Ulf Landmesser |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | inflammation/vascular inflammation |
| Funding | 755604.00€ 755.604,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
non-coding RNA, inflammation, vascular, endothelium, repair, monocytes, mircoRNA
The project aims to better define mechanisms regulating vascular and cardiac immune and repair responses in cardiovascular diseases. We combine flow cytometric sorting of human monocyte populations and the characterization of their coding and non-coding RNA profiles in relation to monocyte functions. Furthermore, we assess the functional impact of each of the known 2000+ miR species for monocyte-endothelial cell interaction and for cardiomyocyte proliferation. Another sub-project investigates microvesicles and their miR cargo for the interaction between blood leukocyte populations and the endothelium in patients with acute and stable cardiovascular diseases. Finally, we assess the role of lipoproteins for the interaction between cells of the innate immunity and cells of the vascular wall.
| ID | 81Z2100501 |
| Institution | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE) |
| Project leader | Matthias Schulze |
| Site | Berlin |
| Project type | Partner Site Projects |
| Funding | 255239.29€ 255.239,29 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Beobachtungsstudie, Ernährung, körperliche Aktivität, Mortalität, koronare Herzkrankheit
In einer Beobachtungsstudie werden Ernährung und körperliche Aktivität als Risikofaktoren für die Prognose und Mortalität von Patienten mit stabiler koronarer Herzkrankheit untersucht.")
| ID | 81Z2200101 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Stefanie Dimmeler |
| Site | RheinMain |
| Project type | Partner Site Projects | Topic | miRNAS/IncRNA |
| Funding | 1000001.20€ 1.000.001,20 |
| Begin | 2015-05-0101.05.2015 |
| End | 2019-01-3131.01.2019 |
cardiovascular, RNA therapeutics, bioinformatics, biomarker
In frame of this project we would like to strengthen our extensive expertise in non-coding RNA research by appointing two new W2 professorships RNA Therapeutics and Bioinformatics in Cardiovascular Disease at the university hospital in Frankfurt. Dr. Reinier Boon has recently been appointed as professor in RNA Therapeutics and is mainly focusing on the establishment of in vitro and in vivo systems to unravel the role of newly discovered non-coding RNAs, especially lincRNAs, in cardiovascular diseases. The W2 professorship in Bioinformatics in Cardiovascular Disease will provide strong expertise in bioinformatics to support the analysis of large datasets (e.g. microarrays, ChIP and NGS) for the identification of new biomarker and to generate databases mainly focusing on the non-coding Genome.
| ID | 81Z2210101 |
| Institution | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| Project leader | Philipp Wild |
| Site | RheinMain |
| Project type | Partner Site Projects |
| Funding | 2431414.02€ 2.431.414,02 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Heart Failure, vascular function, Biodatabanking, phenomics, cohort study
The Myovasc Study is a prospective cohort study investigating heart failure and its interactions with vascular disease. From January 2013 to January 2017 approximately 3000 participants with asymptomatic and symptomatic heart failure are eligible for the study. The primary outcome of interest is worsening of heart failure, defined as transition of cardiac dysfunction to symptomatic heart failure or cardiac death in asymptomatic individuals and hospitalization or cardiac death in symptomatic heart failure. Study participants start with a 5-hour baseline examination including comprehensive cardiovascular diagnostics. A follow up with the same examination program is performed after 2 and 4 years. A computer-assisted telephone interview with assessment of outcome is conducted yearly.
| ID | 81Z2300121 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Gerd Hasenfuß |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 838625.00€ 838.625,00 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z2400121 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Stephan B. Felix |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | Inflammatory heart diseases |
| Funding | 557511.98€ 557.511,98 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
dilated cardiomyopathy, risk profiles, biomarker, inflammatory processes, animal models, cell culture
The discovery of inflammatory processes involved in the development of cardiomyopathies has lead to the development of new therapies. The aim of this project is to use existing patient cohorts with dilated cardiomyopathy to investigate individual inflammatory risk profiles. Biomaterials will be investigated regarding new factors indicating an individual predisposition for developing the disease or factors influencing the progression of the disease. Generated hypotheses shall be further explored in experimental settings e.g. cell cultures or animal models. The major aim is to create new insights into the pathegenesis of DCM and to develop new diagnostic tools for dilated cardiomyopathy which may be also relevant for new therapeutic approaches.
| ID | 81Z2500101 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Benjamin Meder |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects |
| Funding | 2364295.84€ 2.364.295,84 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
cardiomyopathy, genetics, epigenetics
The project investigates the genetic and epigenetic mechanisms involved in the pathogenesis of cardiomyopathies. It further studies the connection of genetics and inflammatory heart disease on the clinical and molecular level.
| ID | 81Z2500102 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Hugo A. Katus |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects |
| Funding | 768615.15€ 768.615,15 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z2500103 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Hugo A. Katus |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects |
| Funding | 1812188.44€ 1.812.188,44 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z2500104 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Patrick Most |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | DNA/RNA based, protein based therapy |
| Funding | 525688.20€ 525.688,20 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Heart failure gene therapy efficacy parameter & biomarker, Disease- & ligand-controlled expression systems
To enable the design of meaningful clinical trial protocols for future heart failure gene therapy programs, this project aims to determine optimized parameters of therapeutic efficacy (work package 1), viral vectors (work package 2) and predictive biomarkers (work package 3) for DNA-based therapeutic targets/ATMP against chronic heart failure such as S100A1 and others. In addition, this project seeks development of disease- (work package 4) and ligand-controlled (work package 5) gene expression systems suitable for the human-sized heart to overcome limitations of currently used constitutive systems.
| ID | 81Z2500105 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Patrick Most |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | DNA/RNA based, protein based therapy |
| Funding | 555342.14€ 555.342,14 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Peptide- and mRNA-based therapeutic molecules, heart failure, Cor pulmonale
Unmet clinical needs such as heart failure or Cor pulmonale fuel our interest in pharmacological strategies that improve cardiac performance by bypassing cAMP signaling and extend to the mitigation of tachyarrhythmia susceptibility, energy defects and adverse remodeling. To this end, this project seeks to determine therapeutic efficacy and safety/toxicology of S100A1 synthetic peptide- (working package 1a/b) and in vitro transcribed mRNA-based (working package 2a/b) experimental therapies against disorders of the left and right ventricular chambers in in vitro and in vivo models.
| ID | 81Z2500201 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Martin Borggrefe |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | iPSC |
| Funding | 587627.67€ 587.627,67 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
iPS, arrhythmias, Patch-clamp
Investigation of underlying mechanisms and identification of new therapeutic targets: hiPSC-CMs possess characteristics similar to that of native human cardiomyocytes and can model the main features of some heart diseases. They provide a new platform to study the disease pathology and screen drugs. The aim of our study is to use the hiPSC-CMs modeling the arrhythmogenic heart diseases (SQTs, LQTs, Brugada syndrome, ARVC, HCM and DCM) for studying the underlying mechanisms and identifying new therapeutic targets for the treatment of the diseases. In addition, we will test effects of drugs on the diseased hiPSC-CMs and design better drug treatments for the diseases
| ID | 81Z2500202 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Martin Borggrefe |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 260605.23€ 260.605,23 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Detection of fibrosis, epicardial adipose tissue, Na+-Imaging
Detection of fibrosis using CMR: In patients with cardiomyopathies we want to investigate the diagnostic value of T1 mapping in comparision to late gadolinium enhancement imaging for the evaluation of fibrosis. Epicardial adipose tissue: In patients with cardiomyopathies we want to correlate changes in epicardial adipose tissue to morphological and functional parameters as well as outcome. Na+-Imaging: In cooperation with the Institute of Computer Assisted Clinical Medicine (Prof. Dr. rer. Nat L. Schad) we aime to examine the feasibility of 23Na+ heart imaging with a double-resonant 23Na-1H surface RF coil at 3 T.
| ID | 81Z2500203 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Martin Borggrefe |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 124296.31€ 124.296,31 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
outcome, CMR imaging, ICD implantation, benefits, risks
Identification of prognostic relevant risk factors
In patients with cardiomyopathies and arrhythmias we aim to improve prognosis through clinical interventions. Therefore the identification of outcome-relevant parameters is crucial. In patients who underwent CMR-imaging prior to primary or secondary ICD implantation we aim to investigate which patient-specific and CMR parameters are relevant for reaching a primary or secondary endpoint. Besides, we want to find out in which patients the benefits of the lifesaving ICD implantations outweigh the risk of device associated complications.
| ID | 81Z2500204 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Martin Borggrefe |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | other arrhythmias |
| Funding | 243188.46€ 243.188,46 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
primary electrical disease of the heart, channelopathies, risk stratification
Registry for primary electrical disease of the heart: Channelopathies are a heterogeneous group of disorders resulting from the dysfunction of ion channels located in the membranes of all cells. Channelopathies are diseases that develop because of defects in ion channels caused by either genetic or acquired factors . In patients with inherited channelopathies phenotype, individual disease course and mechanisms of arrhythmogenesis are quite different among individual patients. While in some patients causes and genetic background of ventricular fibrillation are better understood, others will develop ventricular fibrillation of unknown cause. The clinical phenotype might be influenced by unknown genetic mutations, epigenetic modifiers, gender or other still unkown risk factors. Therefore, the aim of our registry for primary electrical disease of the heart, is to identify genetic and epigenetic factors which may cause lethal arrhythmias as a result of dysfunctioning cardiac ion channels.
| ID | 81Z2500205 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Thomas Wieland |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | cardiomyocyte function |
| Funding | 611112.45€ 611.112,45 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
cardiac contractiliy,muscarinic receptors, RhoGTPases, RhoGTPase-activating proteins, RhoGTPase guanine nucleotide exchange factors,
In this project molecular targets in a novel positive inotropic pathway coupling M2 muscarinic receptors to RhoA/Rho-kinase in heart failure are characterized and validated. The so far identified targets are the Regulator of G-protein signaling RGS3, the RhoGTPase-actvating protein p190RhoGAP and the guanine nucleotide exchange factor Tiam1. Depending on the expression level of RGS3 this proteins allow for a switch of the coupling of M2 muscarinic receptors to a Rho-kinase dependent positive inotropic response in cardiac myocytes. Therefore, all three proteins are putative molecular targets for novel therapies in heart failure.
| ID | 81Z2500206 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Jochen Utikal |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects | Topic | iPSC |
| Funding | 212254.57€ 212.254,57 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-05-3131.05.2018 |
iPSC, repogramming, skin, fibroblast, cardiomyocyte
Generation of induced pluripotent stem cells (iPSCs) from patients with heart diseases, their differentiation in cardiomyocytes and their use in functional protocols
| ID | 81Z2500301 |
| Institution | Deutsches Krebsforschungszentrum (DKFZ) |
| Project leader | Christoph Plass |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects |
| Funding | 263917.41€ 263.917,41 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z2500401 |
| Institution | Europäisches Laboratorium für Molekularbiologie (EMBL) |
| Project leader | Eileen Furlong |
| Site | Heidelberg/Mannheim |
| Project type | Partner Site Projects |
| Funding | 125505.72€ 125.505,72 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z2700101 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 270000.00€ 270.000,00 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
Nexilin, Cardiomyopathy, Cardiomyocytes, iPS cells
Nexilin is one of the key genes, which have recently been identified by our group to play a critical role in cardiomyopathy. Our research interest is the evaluation of the functional role of nexilin in dilated cardiomyopathy (DCM) using constitutive and conditional mouse models as well as cardiomyocytes differentiated from human induced pluripotent stem cells (iPS cells).
| ID | 81Z2700121 |
| Institution | Universität zu Lübeck |
| Project leader | Jeanette Erdmann |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects |
| Funding | 355555.48€ 355.555,48 |
| Begin | 2011-10-1515.10.2011 |
| End | 2016-03-3131.03.2016 |
| ID | 81Z2700201 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Norbert Frey |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 1231634.31€ 1.231.634,31 |
| Begin | 2014-11-0101.11.2014 |
| End | 2018-12-3131.12.2018 |
non-coding RNAs, lncRNA, MicroRNA
Non-coding RNAs, including micro-RNAs and lncRNAs, have been shown to play a critical role in the regulation of gene expression. It is estimated that about 4.000 lncRNAs exist, yet little is known about the role of lncRNAs in cardiac remodeling and heart failure. We thus hypothesize that lncRNAs may significantly contribute to the pathogenesis and progression of heart failure. Specifically, we aim to identify differentially regulated lncRNAs in animal models as well as human heart failure. These data will be bioinformatically analyzed and correlated with cDNA and miRNA expression. In addition, we plan a comprehensive functional characterization of novel cardiac lncRNAs utilizing adenoviruses encoding for lncRNAs and inhibitors, respectively, as well as generation of transgenic animal models. Finally, we aim to explore novel therapeutic options via experimental manipulation of specific lncRNAs in vitro and in vivo
| ID | 81Z2700202 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Hans-Heiner Kramer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects |
| Funding | 445266.19€ 445.266,19 |
| Begin | 2014-11-0101.11.2014 |
| End | 2018-12-3131.12.2018 |
hypoplastic left heart syndrome, DNA methylation, whole exome sequencing, zebrafish
Hypoplastic left heart syndrome (HLHS) displays one of the most severe cardiac malformations that encompasses a spectrum of structural defects characterized by atresia or stenosis of the aortic and mitral valve, as well as a hypoplasia of the left ventricle and aorta. In order to analyze genetic and transcriptomic changes potentially involved in the pathogenesis of HLHS, whole exome sequencing and RNA sequencing is performed on heart tissue samples from independent cases. To evaluate epigenetic alterations, DNA methylation profiles are being analyzed. Identified candidate genes are characterized using zebrafish model organism and furthermore, patient-specific inducible pluripotent stem cells are analyzed to provide a contribution for a better understanding of the etiology of HLHS.
| ID | 81Z2700203 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Georg Lutter |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | stem cells/cardiac regeneration |
| Funding | 280000.00€ 280.000,00 |
| Begin | 2014-11-0101.11.2014 |
| End | 2018-12-3131.12.2018 |
tissue engineering, endothelial progenitor cells, cell seeding, polymeric scaffolds
Tissue engineering is an upcoming technique for heart valve replacement, providing a living valve, capable of growth and biological integration. Heart valves made of synthetic polymers such as polyurethanes exhibit biocompatibility, bioresorbability and excellent mechanical properties with high durability. Endothelial progenitor cells (EPCs) are ideal candidates for vascular regenerative therapy, as they participate in blood vessel formation and incorporate into damaged vascular structure. In this project, the optimal conditions for administration of EPCs on polymeric scaffolds will be improved. Functionality, biocompatibility, inflammatory capacity and biological integrity of these engineered valved stents will be analysed in vivo (sheep model) for human cardiovascular application.
| ID | 81Z2710101 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Arne Hansen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | stem cells/cardiac regeneration |
| Funding | 1556334.48€ 1.556.334,48 |
| Begin | 2014-10-2929.10.2014 |
| End | 2019-02-2828.02.2019 |
Engineered heart tissue, guinea pig kryo injury model, cardiac repair
The project aims to unravel mechanisms of human engineered heart tissue (EHT) mediated cardiac repair. The project is based on a guinea pig kryo injury EHT transplant model and addresses coupling, EHT morphology after tranplantation, cardiomyocyte proliferation among others.
| ID | 81Z2710102 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Lucie Carrier |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 692627.97€ 692.627,97 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
Cardiomyopathy, Hypertrophy, iPSC, CRISPR/Cas9, disease modeling
Goals of this project are : i) to search for mutations in patients with HCM and to evaluate the molecular pathways in several human samples (blood, septal myectomies, skin biopsy); ii) to model HCM in the dish in both 2D culture of cardiac myocytes and 3D engineered heart tissues (EHT) obtained from iPSC-derived from HCM patients skin biopsy. Evaluation of contractile function and electrophysiological properties. iii) to evaluate different molecular therapies in human cardiac myocytes and EHT. Therefore, we also plan to use the CRISPR-Cas9 technology to remove the mutation in iPSC, which will be then used as controls for disease phenotype and molecular therapy.
| ID | 81Z2710103 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Heimo Ehmke |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | cardiomyocyte function |
| Funding | 307489.08€ 307.489,08 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
acute mechanical unloading, Ca2+ cycling, phospholamban, Ca2+ channel, cardiac arrhythmias, SERCA2, heart transplantation
Cardiac mechanical unloading is associated with an increased risk of ventricular arrhythmias. Underlying pathophysiological mechanisms are still poorly understood. Recent studies indicate that unloading causes a remodeling of Ca2+ homeostasis in ventricular cardiomyocytes leading to a reduced contribution of sarcoplasmic reticulum (SR) Ca2+ release to the systolic Ca2+ transient. Using pharmacological and genetic interventions in a rodent model of cardiac unloading, this project tests the hypothesis that reestablishing the dominance of SR Ca2+ release will stabilize cardiac repolarization and therefore reduce the occurrence of arrhythmias.
| ID | 81Z2710104 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Stephan Willems |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | other arrhythmias |
| Funding | 386990.40€ 386.990,40 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
arrythmias, atrial fibrillation, Hypertension, Left ventricular hypertrophy, cardiac nervous system
The development of cardiac fibrosis and a higher susceptibility of atrial fibrillation (AF) have been shown in an animal model of long-term hypertension. However, the causal relationship between hypertension, fibrosis and AF remains unclear. Using Angiotensin II, we have established a long-term hypertension model in sheep in order to elucidate structural and electrophysiological changes as a prerequisite for AF. Since the intrinsic cardiac nervous system (ICANS) is known affect AF and other arrhythmias and might present a potential target for catheter-based interventions, we additionally characterise the role of the ICANS in arrhythmias using our sheep model.
| ID | 81Z2710105 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Sonja Schrepfer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | stem cells/cardiac regeneration |
| Funding | 320582.89€ 320.582,89 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
cardiac regeneration; islet cell regeneration; regenerative medicine; immunobiology of pluripotent stem cells; stem cell rejection
Due to ethical concerns, the derivation of induced pluripotent stem (iPS) cells seems to be a novel, promising tool. However, the generation, validation, differentiation and puri-fication of iPS cells takes weeks to months and therefore, patient-specific iPS cells will not be readily available for acute diseases such as myocardial infarction or stroke. For this purpose, off-the-shelf cell products (e.g., iPS cell-derived cardiac and neuronal cells) will be required to be administered in a timely fashion. These cells, however, would not be patient-specific, but allogeneic. Since systemic immunosuppression for iPS cell recipients is not justifiable and feasible for cell therapy, we are aiming to understand their immune rejection and subsequent generate hypo-immunogenic cells that allow universal allogeneic transplantation without inducing immune activation, thereby evading rejection.
| ID | 81Z2710106 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Friederike Cuello |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | cardiomyocyte function |
| Funding | 340241.71€ 340.241,71 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
Signalling pathways in cardiovascular disease, Protein kinase, Redox regulation
The groups research aims to increase the understanding of the molecular mechanisms of heart failure. In particular, we study how signals from the sympathetic nervous system are transduced into the cardiac myocyte, which processes are subsequently triggered and what molecular alterations occur during heart failure development. Over the past years, we have concentrated our attention on the redox-regulation of protein kinase signalling and the effect on posttranslational regulation of kinases and their substrates. Through this, we have recently established disease-specific posttranslational fingerprints of the myofilament proteome in human heart failure tissue by combining interdisciplinary techniques such as molecular biology and redox-proteomics analyses.
| ID | 81Z2710107 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Dirk Westermann |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 292596.06€ 292.596,06 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
Heart failure, extracellular matrix, inflammation
Our goal is to describe molecular mechanisms involved in heart failure pathology. Therefore, our research is focused on the extracellular matrix remodelling and the regulation of cardiac inflammation in different types of heart failure. Different animal models were used to induce heart failure. Furthermore, we combine in vivo animal models with in vitro cell culture experiments as well as the analysis of human samples to describe molecular mechanisms involved in heart failure pathology. Special focus will be on cardiac remodeling and changes in the extracellular matrix.
| ID | 81Z2710108 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Viacheslav Nicolaev |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 491801.84€ 491.801,84 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
cAMP, microdomains, hypertrophy, beta-blocker, AAV, genetherapy
The ubiquitous second messenger cAMP plays central roles in the regulation of cardiac function and diseases such as hypertrophy and heart failure. Especially the stimulation of cardiomyocyte ?-adrenoceptors leads to strong contractile response and disease progression, while other membrane receptors coupled to the stimulatory G-protein (Gs) play less prominent role. Beta-blockers are therefore central to the therapy but lead to non-cardiac side-effects which limit patient compliance. This project will test the hypothesis that cardiomyocyte-specific delivery of a dominant negative Gs mutant should provide beneficial antihypertrophic effect without systemic side-effects. This mutant will be studied in mouse diseased models and introduced into AAV for gene therapy studies.
| ID | 81Z3100231 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Carsten Tschöpe |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | Inflammatory heart diseases |
| Funding | 397144.32€ 397.144,32 |
| Begin | 2014-01-0101.01.2014 |
| End | 2018-12-3131.12.2018 |
collagen, LoxL-2
Left ventricular stiffness and diastolic dysfunction are besides a raise in collagen/matrix also due to an increased crosslinking of the matrix. Lysyloxidases (LOX) are a family of extracellular matrix crosslinking enzymes and critical contributors to the development of cardiac fibrosis. Besides LOX1, particularly LOX-like (LOXL)-2 is an important target since inhibition of LOXL2 has been shown to result in a marked reduction in activated fibroblasts (myofibroblasts), decreased production of cytokines, and decreased TGF-? pathway signaling. Furthermore, higher serum LOXL2 levels have been shown to be associated with increased risk for idiopatic pulmonary fibrosis disease progression. Importantly, LOXL2 is besides the heart expressed in the spleen and the thymus. Given the importance of the cardiosplenic axis in heart failure, linking inflammation with cardiac fibrosis on the one hand, and the expression of LOXL2 in the spleen/thymus and their antifibrotic features on the other hand, a role of LOXL2 in the inflammation and fibrosis process in heart failure is suggested. This project is focused at evaluating the role of LOXL2 in heart failure with preserved ejection fraction (HFpEF). Therefore, cardiac expression of LOXL2 will be evaluated in HFpEF and heart failure with reduced ejection fraction (HFrEF) patients and the effect of LOXL2 on TGF-ß signaling in cardiac fibroblasts from HFpEF and HFrEF patients analyzed. There will be evaluated whether serum LOXL2 levels are a predictive biomarker for cardiac LOXL2 expression and HFpEF, and whether LOXL2 inhibition may abrograte the progression of cardiac fibrosis.
| ID | 81Z3100331 |
| Institution | Deutsches Herzzentrum Berlin |
| Project leader | Volkmar Falk |
| Site | Berlin |
| Project type | Partner Site Projects |
| Funding | 2196899.52€ 2.196.899,52 |
| Begin | 2011-10-0101.10.2011 |
| End | 2020-12-3131.12.2020 |
| ID | 81Z3100333 |
| Institution | Deutsches Herzzentrum Berlin |
| Project leader | Felix Berger |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 681214.79€ 681.214,79 |
| Begin | 2013-01-0101.01.2013 |
| End | 2018-12-3131.12.2018 |
cardiomyopathy, heart failure, MRI, genetic analysis, disease mechanisms
Pediatric cardiomyopathies are genetically heterogeneous and information on the epidemiology and outcomes of cardiomyopathy in children is limited by disease diversity and small case series. In order to specifically identify patients that would profit from early intervention such as an implantable cardioverter defibrillator (ICD) or specific pharmacologic treatment for heart failure we study individuals <= 18 years and their first-degree relatives with the following phenotypes: Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Left ventricular noncompaction cardiomyopathy (LVNC), and Arrhythmogenic right ventricular cardiomyopathy (ARVC). Detailed phenotyping including MRI and genotyping with a Next Generation Sequencing Panel of 170 candidate genes is performed.
| ID | 81Z3300131 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Stefan Anker |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 2507359.56€ 2.507.359,56 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z3300132 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 1272587.13€ 1.272.587,13 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z3300232 |
| Institution | Deutsches Primatenzentrum Gesellschaft mit beschränkter Haftung - Leibniz-Institut für Primatenforschung |
| Project leader | Rüdiger Behr |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 1629344.24€ 1.629.344,24 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z3400131 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Marcus Dörr |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | cardiomyocyte function |
| Funding | 1476780.81€ 1.476.780,81 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
heart failure, HFrEF, HFpEF, risk profiles biomarker, animal models, TAC, cell culture
The aim of this project is to identify risk profiles which are associated with the development of systolic and diastolic left ventricular dysfunction (HFrEF/ HFpEF). Based on populations-based data new knowledge should be generated regarding the general population. Furthermore patient cohorts (GANI_MED) in an early asymptomatic disease stage shall be investigated to identify factors and mechanisms which indicate or lead to the transition to symptomatic heart failure. Generated hypotheses will be validated and further investigated by cell and animal model based experimental approaches. The major aim is to identify new targets and mechanisms that can be tackled in new prevention and therapeutic approaches in early stages of heart failure to inhibit disease progression.
| ID | 81Z3600431 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Partner Site Projects | Topic | DNA/RNA based, protein based therapy |
| Funding | 2107648.12€ 2.107.648,12 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
miRNA-based therapy, microRNA, AntagomiR, anti-miR, AAV
This project aims to develop RNA-based therapeutics that interfere with myocardial damage. For this purpose several cardiovascular microRNAs have been identified and functionally characterized with regard to their capacity to regulate key cellular signaling pathways. A subset of these miRNAs are being validated in mouse models of disease and approaches for their therapeutic manipulation are being developed. This involves studies that aim to optimize the pharmacokinetics and pharmacodynamics of miRNA inhibitor molecules.
| ID | 81Z4300141 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Stephan Lehnart |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 1445283.03€ 1.445.283,03 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z4300441 |
| Institution | Max-Planck-Institut für Dynamik und Selbstorganisation |
| Project leader | Stefan Luther |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 1584621.95€ 1.584.621,95 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z4600241 |
| Institution | Klinikum der Universität München |
| Project leader | Stefan Kääb |
| Site | München |
| Project type | Partner Site Projects |
| Funding | 638105.71€ 638.105,71 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z5100251 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Joachim Spranger |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | arteriosclerosis |
| Funding | 1206113.23€ 1.206.113,23 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
Metabolism, brain-heart axis, diabetes, NAFLD, prevention
We aim to identify novel and further elucidate known endogenous metabolic modifiers of cardiovascular health. We analyze the interrelation between environment, novel metabolic targets and CVD in relation to age and pre-existing CVD to finally translate those findings into preventive practice. We use established mouse models of metabolic disease (obesity, insulin resistance, NAFLD) and analyse the role of specific molecular targets in rodents. We particularly test selected interventional strategies (incl. pharmacology). This is combined with clinical studies in cohorts with impaired metabolism and increased cardiovascular risk (e.g. obesity, diabetes, insulin resistance)
| ID | 81Z5100254 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Ulrich Kintscher |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 554977.80€ 554.977,80 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
lipids, metabolism, heart failure
This study aims to investigate the preventive actions of new lipid mediators on myocardial hypertrophy and heart failure. We could recently show that palmitoleic acid (C16:1n7) promotes the development of physiological cardiac remodeling (Foryst-Ludwig A, J Biol Chem 2015). In continuation of this, we are now focusing on new ?-3 fatty acids. We will test the anti-hypertrophic/ anti-fibrotic potential of anti-inflammatory lipid mediators such as resolvins, protectins und maresins in different disease models such as TAC or isoprenalin injection.
| ID | 81Z5300151 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Christoph Herrmann-Lingen |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 484269.80€ 484.269,80 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z5400151 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Marcus Dörr |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | Inflammatory heart diseases |
| Funding | 2432615.37€ 2.432.615,37 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
deep phenotyping, standarized phenotyping, examination centre, exercise training centre
This project aims to create a new infrastructure for conducting clinical trials by establishing a cardiovascular examination and training centre. This centre will carry out the standardized and quality controlled phenotyping of probands and patients. This includes algorithms for standardized data export and analysis. Methods for phenotyping include: standardized interviews and questionnaires, anthropometry, digital ECG, echocardiography, resting and 24 h blood pressure measurement, bodyplethysmography, spiroergometry, IMT measurements, peripheral endothelial function (FMD, EndoPAT), ankle-brachial-index measurements, pulse wave measurements (Vascular Explorer). Furthermore, training facilities will be established for conductiong cardiovascular prevention studies with life-style intervention programmes e.g. exercise.
| ID | 81Z5400152 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Ulrich John |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | Inflammatory heart diseases |
| Funding | 1344601.62€ 1.344.601,62 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
expert feedback systems, behavioural changes, primary prevention, physical activity, motivation, adherence life-style changes
The aim of this project is to investigate how to reach relevant patient groups for primary prevention of cardiovascular diseases. Furthermore, automated intervention tools and feedback systems shall be developed which can be easily used in CVD prevention studies to increase motivation and adherence to life-style changes. Additionally, pilot studies and RCTs will be conducted to reduce sedentary behaviour as one major cardiovascular risk factor and to increase daily physical activity. A W2 professorship will be established to provide profound knowledge for prevention and behavioural change approaches e.g. exercise training and to support the other partner side projects especially those dealing with heart failure and coronary heart disease.
| ID | 81Z5400153 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Marcus Dörr |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | Inflammatory heart diseases |
| Funding | 1319066.03€ 1.319.066,03 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
exercise training, secondary prevention, biomarker profiles, heart failure, molecular cardiology
This projects aims to develop new life-style intervention approaches for secondary prevention of heart failure (HFrEF/HFpEF) and coronary heart disease. Pilotstudies will investigate the effects of life-style changes mainly exercise training on cardiovascular surrogate parameters and disease progression. Additionally, intervention-related biomarkers shall be investigated using transcriptomics, proteomics and metabolomics (urine, plasma, whole blood) which can be used as monitoring factors during intervention or as predictive factors for disease progression. The major aim is to find suitable surrogate paramters which can be easily implemented into large prevention RCTs and can be used to amplify the positive effects of life-style changes by increasing motivation and therapy complience and adherence. A W2 professorship for molecular cardiology will be established to support the investigation of prevention approaches and to interact with and support the other partner site projects.
| ID | 81Z5600151 |
| Institution | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Project leader | Annette Peters |
| Site | München |
| Project type | Partner Site Projects | Topic | arteriosclerosis |
| Funding | 895595.21€ 895.595,21 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
changes in cardiovascular risk factors, epigenetics, environmental factors, system biology
The aim of the DZHK project Cardiovascular Population Studies (MHA 5.1) is to identify novel risk factors to improve individual risk prediction. The last years showed that especially epigenetics and metabolic processes have great potential to elicit so far unknown pathomechanisms. The focus is on short-term triggers of myocardial infarction as well as long-term risk factors that influence arteriosclerosis. A junior research group was established to integrate life-style factors, environmental factors, epigenetic markers and blood biomarkers from the KORA study. Their relative impact are investigated using innovative methods. All data is available via KORA.PASST.
Tasks:
1. Risk factors for coronary heart disease which changes occurred in the last 30 years?
2. OMICs and novel methods from system medicine to investigate the etiology of coronary heart disease.
3. Environmental factors and coronary heart disease.
| ID | 81Z5600153 |
| Institution | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Project leader | Thomas Meitinger |
| Site | München |
| Project type | Partner Site Projects |
| Funding | 621714.66€ 621.714,66 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z5600551 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 882711.61€ 882.711,61 |
| Begin | 2013-01-0101.01.2013 |
| End | 2018-12-3131.12.2018 |
coronary artery disease, myocardial infarction, networks, pathway analysis, risk prediction
Our group has substantially contributed to the discovery of numerous genomic variants, which increase the risk of coronary artery disease. Based on these variants, we were able to evaluate the prospective value of a genetic risk score in a large sample set. Using novel bioinformatics techniques, we identified novel networks and pathways influencing the pathophysiology of coronary artery disease and myocardial infarction. The goal of the project Clinical genomics, risk prediction is to explore the interaction of known and yet to be identified coronary artery disease risk loci as well as the interaction of coronary artery disease risk loci with environmental factors to ultimately improve risk prediction.
| ID | 81Z6100161 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Thoralf Niendorf |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 271100.00€ 271.100,00 |
| Begin | 2014-01-0101.01.2014 |
| End | 2018-12-3131.12.2018 |
ultrhahigh field MRI, human studies
This project builds on the achievements of our previous GCCR project. It focuses on the development of enabling radiofrequency (RF) antenna technology tailored for high spatial resolution cardiac magnetic resonance imaging (MRI) at a magnetic field strength of 7.0 Tesla. To meet this objective multi-channel transmission RF antenna arrays will be designed. For this purpose novel dipole antenna building blocks will be developed, implemented and validated. The clinical feasibility of the novel technology will be evaluated in a volunteer study at 7.0 Tesla with the ultimate goal to enable sub-millimeter spatial resolution cardiac MR imaging that supports visualization of subtle cardiac anatomy, high fidelity cardiac chamber quantification and imaging based myocardial tissue characterization.
| ID | 81Z6100162 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Thoralf Niendorf |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 200000.00€ 200.000,00 |
| Begin | 2014-01-0101.01.2014 |
| End | 2018-12-3131.12.2018 |
CMR imaging, experimental and human studies
CMR has the capability to differentiate myocardial injury applying different techniques. There are increasing numbers of quantitative approaches but an integrative quantitative covering various pathologies is missing. A a non-rigid registration method to superimpose focal images and diffuse fibrosis imaging allowing for pixel-wise comparison could already be developed. Further efforts are focusing on the integration of other pathologies in fused images. The project is based on theoretical phantoms, in vitro phantoms leading to human studies.
| ID | 81Z6200161 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Eike Nagel |
| Site | RheinMain |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 2890029.02€ 2.890.029,02 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
magnetic resonance, computed tomography, myocardial ischaemia, heart failure, inflammation, fibrosis
The Imaging Project at the University Hospital Frankfurt (Rhein-Main) is represented by a DZHK-Professor for Cardiovascular Imaging and equipped with a state-of-the art 3T MR scanner dedicated for cardiovascular research since May 2016. In October 2016 a state-of-the art CT scanner dedicated for cardiovascular research will be installed. The projects focus on the main areas of cardiovascular disease, such as ischaemia, inflammation, fibrosis and heart failure as well as the prediction and substrate for arrhythmia. Novel diagnostic strategies (such as real time imaging, fully quantitative perfusion imaging and tissue characterisation) are developed, validated for accuracy, reproducibility, transferability, outcome and reversibility the effects of therapeutic interventions are assessed.
| ID | 81Z6300161 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Joachim Lotz |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 1118414.54€ 1.118.414,54 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z6300162 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Stephan Lehnart |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 721675.11€ 721.675,11 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z6300561 |
| Institution | Max-Planck-Institut für Biophysikalische Chemie |
| Project leader | Jens Frahm |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 605859.47€ 605.859,47 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z6300562 |
| Institution | Max-Planck-Institut für Biophysikalische Chemie |
| Project leader | Stefan W. Hell |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 822288.33€ 822.288,33 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z6600262 |
| Institution | Klinikum der Universität München |
| Project leader | Reiser |
| Site | München |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 689563.18€ 689.563,18 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
MRI, CT, 4D-flow MRI, T1-mapping, large vessel vasculitis, 3D-Blackblood, OSAS, TAVI
Biomarker Imaging develops diagnostic, prognostic and predictive CT and MRI biomarkers for heart disease and establishes them in clinical routine. This includes:
Validation and standardization of recording and evaluation techniques of 4D flow MRI in children
Characterization of diffuse myocardial fibrosis in hereditary cardiomyopathy using pre- and post-contrast T1-mapping
Contrast dose optimization in CT angiography for determining the size of the aortic annulus before TAVI
Evaluation of non-invasive imaging methods without radiation exposure for primary diagnostic imaging and assessment of large vessel vasculitis
Evaluation of the effect of obstructive sleep apnea syndrome (OSAS) on cardiac function as determined by MRI
| ID | 81Z6600661 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Markus Schwaiger |
| Site | München |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 392617.58€ 392.617,58 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
imaging atherosclerotic plaques,
macrophage infiltration,
Tilmanocept
plaque inflammation,
tracer development, CXCR4, Ga-68-pentixafor, acute myocardial infarction, post-ischemic inflammation, FDG-PET/MRI
The aim of this project is to develop multimodal imaging strategies with a focus on inflammatory processes in atherosclerosis and in the sub-acute phase after myocardial infarction. For this purpose tracers targeting inflammatory processes (such as activated macrophages) are being developed. One such example is the tracer Tilmanocept which binds specifically to mannose-receptors on the surface of macrophages. Tilmanocept has originally been developed to image sentinel lymph nodes and was therefore labeled with radionuclides ideal for conventional gamma cameras. In our research group Tilmanocept is being modified so that positron emitting radionuclides, particularly Gallium-68, can be attached to Tilmanocept. Furthermore, the structure of Tilmanocept is being adapted to improve the affinity and biodistribution of this tracer. First biodistribution data in Apo-E-mice demonstrated an increased uptake in atherosclerotic plaques.
Another focus of our research is the evaluation of Ga-68-pentixafor a PET-tracer binding with nanomolar affinity to the chemokine receptor 4 (CXCR4). CXCR4 is known to be overexpressed on activated, hypoxic macrophages therefor CXCR4 seems to be a very promising target to image inflammatory processes in atherosclerosis. In a rabbit model of atherosclerosis this approach has already been evaluated. New Zealand White rabbits fed with a high cholesterol diet received an endothelial abrasion of the right carotid artery and of the abdominal aorta to induce atherosclerotic plaque formation. Studies were performed using Ga-68-pentixafor (for imaging studies) and I-125-pentixafor (for biodistribution studies). We were able to demonstrate that tracer uptake was increased in atherosclerotic lesions and could be blocked efficiently by AMD3100 a CXCR4-inhibitor. CXCR4-immunohistochemistry staining showed a high correlation with tracer uptake in autoradiography. These results are the basis for a DZHK-funded project with the aim to evaluate Ga-68-pentixafor in humans with carotid plaques in comparison to F-18-FDG.
Besides these experiments to study inflammatory processes in atherosclerotic plaques, a large number of clinical studies to investigate the post-ischemic inflammatory response after myocardial infarction have been conducted. Patients were imaged in the first few days after myocardial infarction on an integrated PET/MR scanner using F-18-FDG as radiotracer. Patients had to fast for >12 hours and received heparin before tracer injection in order to suppress physiological F-18 FDG uptake in remote myocardium. The area of F-18 FDG uptake showed a high correlation with the area at risk and was significantly larger than the infarcted area (the latter was determined by late gadolinium enhancement MRI). Interestingly, the intensity of F-18 FDG uptake as a measure of post-ischemic inflammation correlated inversely with left ventricular function after 6 months, i.e. the higher the inflammatory signal the more likely an increase in endsystolic/end-diastolic volume and a decrease in ejection fraction was observed. While preclinical rodent studies clearly suggest that the F-18 FDG uptake reflects the invasion of inflammatory cells into the post-ischemic myocardium, no large animal study has proven this hypothesis. That is the reason why our group initiated first large animal studies with the aim to further breakdown this novel biosignal.
| ID | 81Z7100201 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Vera Regitz-Zagrosek |
| Site | Berlin |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 407195.97€ 407.195,97 |
| Begin | 2014-08-0101.08.2014 |
| End | 2018-12-3131.12.2018 |
mouse models, echocardiography (mice, rats), training
Establishment of DZHK-core facility for imaging, telemetric and metabolic measurements of rodents
| ID | 81Z7200101 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Ralf Brandes |
| Site | RheinMain |
| Project type | Partner Site Projects | Topic | Mechanisms in ischemia/reperfusion |
| Funding | 1130050.21€ 1.130.050,21 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
mouse imaging, mouse Phenotyping
The core facility provides a platform for animal phenotyping within the DZHK. SOPs for angiogenesis assays, animal imaging, myocardial infarct models are provided and novel Assays are developed such as virtual histology and xenograph angiogenesis models.
| ID | 81Z7200175 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III |
| Project leader | Eva Herrmann |
| Site | RheinMain |
| Project type | Partner Site Projects |
| Funding | 104989.68€ 104.989,68 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
biostatistics, mathematical modelling, survival analysis, sample size calculation
The aim of this project is the development of new statistical tools, especially in form of easy to use R package with a graphical user interface. These tools should especially comprise sample size calculation tools, survival analysis tools and graphical illustrations of the analysis of longitudinal data which directly refer to needs of basic science and clinical projects in the DZHK. These packages will be available under the GNU licence for open software products.
| ID | 81Z7200301 |
| Institution | Max-Planck-Institut für Herz- und Lungenforschung |
| Project leader | Thomas Braun |
| Site | RheinMain |
| Project type | Partner Site Projects |
| Funding | 1943239.54€ 1.943.239,54 |
| Begin | 2015-01-0101.01.2015 |
| End | 2018-12-3131.12.2018 |
cardiovascular research, mass spectrometry-based proteomics, protein quantification, post-translational modificationv
Biomolecular mass spectrometry facility in Bad Nauheim provides service in state-of-the-art liquid chromatography and tandem mass spectrometry for all members of the DZHK. Cardiovascular diseases are multicausal and result from altered cellular processes. Therefore, changes within the proteome or incorrect signaling pathways need to be characterized to understand the molecular mechanisms of heart failure. Our facility enables proteomic approaches to identify and quantify protein expression, post-translational modifications and protein-protein interactions. Furthermore, we aim for establishing new methods to optimize proteomics for cardiovascular research.
| ID | 81Z7300171 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Wolfram-Hubertus Zimmermann |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 2090025.26€ 2.090.025,26 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z7300173 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Tim Friede |
| Site | Göttingen |
| Project type | Partner Site Projects |
| Funding | 584548.03€ 584.548,03 |
| Begin | 2012-01-0101.01.2012 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z7400171 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Matthias Nauck |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 832828.34€ 832.828,34 |
| Begin | 2013-01-0101.01.2013 |
| End | 2018-12-3131.12.2018 |
metabolomics, metabolic profiles, risk stratification, molecular intervention monitoring
Changes in individual metabolic profiles can give hints on subcliinical deseases and might be a source for the discovery of new biomarkers. Furthermore, metabolic profiles can provide information on specific food consumption habits or environmental exposures. Therefore, measurements of metabolic profiles are the basis for individualized diagnostics and therapy in patients. NMR and mass pectroscopy provide deep insights into metabolom changes in urine or blood plasma samples. The major aim of this project is to provide a platform for investigating metabolic changes due to prevention measure in cardiovascular diseases and to generate new hypotheses for the investigation and development of new diagnostic and theraputic approaches. Data from population-based studies like SHIP or Inter99 will complement these investigations by comparing patient cohorts to the general population. Furthermore, metabolic profiles that can be used as intervention (e.g. exercise training) monitoring tools will be investigated. Finally, a comprehensive data analysis of transcriptome, proteome and metabolome data will be carried out for risk stratification and therapeutic prognosis in DCM and heart failure.
| ID | 81Z7400172 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Uwe Völker |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 1427830.24€ 1.427.830,24 |
| Begin | 2013-01-0101.01.2013 |
| End | 2018-12-3131.12.2018 |
proteomics, transcriptomics, integrated data analysis, risk stratification, molecular intervention monitoring
The identification of new biomarkers from easily obtainable biomaterials like blood or urine is a key in individualized approaches for diagnostics and therapy. Proteomics provides promising approaches that are ivestigated worldwide for many different diseases. The major aim of this project is analyse unique population-based cohorts in Greifswald which can be used as control groups for investigations in patients. Furthermore, proteomics shall provide characterictic proteome profiles for primary and secondary prevention approaches of cardiovascular diseases that can be used for intervention monitoring or as prognostic factors. Complementary transcriptome analyses to baseline and during the intervention (follow-up) will be done and a comprehensive data analysis of transcriptome, proteome and metabolome data will be carried out for risk stratification and therapeutic prognosis in DCM and heart failure.
| ID | 81Z7400173 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Matthias Nauck |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | genetics of cardiovascular diseases |
| Funding | 561219.26€ 561.219,26 |
| Begin | 2014-01-0101.01.2014 |
| End | 2018-12-3131.12.2018 |
biobanking, clinical chemistry, biomarker, integrated molecular approaches
This project provides the platform for longtime storage of biomaterials (blood, urine, DNA) for investigations regarding the discovery of new biomarkers or biomarker profiles with genomic, transcriptomic, proteomic and metabolomic approaches. A fully automated biobank will be used for storage of biomaterials at -80°C. Furthermore, this project provides standardized and quality controlled workflows for obtaining and processing of biomaterials. Finally, all laboratory diagnostic measurements will be carried in this project as interface to the other partner site projects.
| ID | 81Z7400174 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Wolfgang Hoffmann |
| Site | Greifswald |
| Project type | Partner Site Projects | Topic | Health services/health systems research |
| Funding | 477719.96€ 477.719,96 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
telemedicine, telemonitoring, IT systems, integrated data management, quality assurance
This project supports the investigation of primary and secondary prevention approaches. The major aim of this project is to develop an integrated IT system for documentation, quality assurance, and data storage and provision for population-based field studies and clinical trials regarding cardiovascular disease prevention. Telemedical approaches like monitoring of physical activity and personalized feedback systems will also be investigated.
| ID | 81Z7600173 |
| Institution | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Project leader | Thomas Meitinger |
| Site | München |
| Project type | Partner Site Projects |
| Funding | 885594.22€ 885.594,22 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
| ID | 81Z7600174 |
| Institution | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Project leader | Martin Hrabé de Angelis |
| Site | München |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 212627.90€ 212.627,90 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
phenoytping, mouse models, echocardiography, electrocardiography, cardiovascular screening
Engineered mouse models are essential tools for cardiovascular research because they facilitate studies of the phenotypic consequences of genetic alterations in a large-scale fashion. We established a cardiovascular screen to investigate such mouse models. We aimed at establishing non-invasive echocardiography of the left and right ventricle, Doppler echocardiography and electrocardiography in awake mice. Our protocol allows the diagnosis of biventricular cardiac pathologies and to study symptom occurrence and disease progression non-invasively in high throughput. Many new cardiac phenotypes have been successfully identified in mice.
| ID | 81Z7600274 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Partner Site Projects | Topic | cardiac hypertrophy/remodeling |
| Funding | 464116.00€ 464.116,00 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
Large animal, pig, acute myocardial ischemia, chronic myocardial ischemia, cardiovascular risk factors
The Large Animal platform offers preclinical models of acute or chronic myocardial ischemia (including cardiovascular risk factors) as well as hypertensive / hypertrophic heart failure in pigs. Besides an ischemia-reperfusion model (60-120min occlusion of a coronary artery, up to 8 weeks follow-up) a model of hibernating myocardium (reducing stent gradual coronary occlusion, loss of function in the target area) and a model of hypertrophic heart failure (percutaneous aortic constriction) is available. These models allow for patient care techniques, instrumentation and catheterization. Therapeutic agents (drugs, viral vectors, microRNA inhibitors and cell therapy) can be tested in systemic or regional (intravascular/intra-myocardial) applications. Besides morphological changes, global and regional myocardial function, myocardial perfusion, inflammation and vascular changes can be analyzed.
| ID | 81Z7600671 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Laugwitz/Moretti |
| Site | München |
| Project type | Partner Site Projects | Topic | iPSC |
| Funding | 707459.52€ 707.459,52 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
induced pluripotent stem cells, disease modelling, drug/intervention testing
The focus of this project is the generation of patient-specific models of monogenic and complex cardiovascular diseases using induced pluripotent stem cells (iPSCs) in order to study the molecular pathways that drive the disease and screen for both genes and drugs that can block the disease onset or progression at a cellular level. We work on optimization of reprogramming methods and differentiation protocols into the cardiovascular lineages as well as the development of high-throughput functional assays and CRISPR/Cas9-based genome editing in iPSCs.
| ID | 81Z7600672 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Klaus Kuhn |
| Site | München |
| Project type | Partner Site Projects | Topic | Health services/health systems research |
| Funding | 143793.43€ 143.793,43 |
| Begin | 2011-10-1515.10.2011 |
| End | 2018-12-3131.12.2018 |
information technology, data integration, biobanking
This project has focused on supporting the integration of databases of the Munich Heart Alliance in order to improve shared access to data. Specific aspects are management of biobank data, integration of data into registers, secondary use of clinical data for research questions, and security/privacy issues in compliance with TMF concepts. Existing software modules have been further developed, and an open source solution will be established.
| ID | 81Z7710101 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Thomas Eschenhagen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Partner Site Projects | Topic | imaging |
| Funding | 243335.92€ 243.335,92 |
| Begin | 2014-10-2929.10.2014 |
| End | 2018-12-3131.12.2018 |
small animal experimentation, echocardiography, core facility
The CVRC Echo Core Facility at the UKE offers all members of the DZHK access to a Visualsonics Vevo 2100® high frequency ultrasonograph for small animals. Transthoracic echocardiography is performed by trained staff. They provide a strong background in the evaluation of animal models and can help design protocols to answer research questions. Researchers are introduced into the handling of the technique and receive support for their individual scientific projects.
| ID | 81X1600205 |
| Institution | Klinikum der Universität München |
| Project leader | Axel Bauer |
| Site | München |
| Project type | Clinical Studies |
| Funding | 59624.23€ 59.624,23 |
| Begin | 2016-02-0101.02.2016 |
| End | 2021-07-3131.07.2021 |
https://smart-mi.dzhk.de/
| ID | 81X1600702 |
| Institution | Ludwig-Maximilians-Universität München |
| Project leader | Ulrich Mansmann |
| Site | München |
| Project type | Clinical Studies |
| Funding | 42000.00€ 42.000,00 |
| Begin | 2016-05-0101.05.2016 |
| End | 2021-07-3131.07.2021 |
https://smart-mi.dzhk.de/
| ID | 81X1300106 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Tim Friede |
| Site | Göttingen |
| Project type | Clinical Studies |
| Funding | 116018.80€ 116.018,80 |
| Begin | 2016-04-0101.04.2016 |
| End | 2024-09-3030.09.2024 |
https://fair-hf2.dzhk.de/
| ID | 81X1710102 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Mahir Karakas |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Clinical Studies |
| Funding | 6417303.02€ 6.417.303,02 |
| Begin | 2016-05-0101.05.2016 |
| End | 2024-09-3030.09.2024 |
https://fair-hf2.dzhk.de/
| ID | 81X1710103 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Mahir Karakas |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Clinical Studies |
| Funding | 37088.48€ 37.088,48 |
| Begin | 2016-07-0101.07.2016 |
| End | 2024-09-3030.09.2024 |
https://fair-hf2.dzhk.de/
| ID | 81X2600702 |
| Institution | Ludwig-Maximilians-Universität München |
| Project leader | Eckhard Wolf |
| Site | München |
| Project type | Translational Research Project |
| Funding | 170759.26€ 170.759,26 |
| Begin | 2016-10-0101.10.2016 |
| End | 2021-11-3030.11.2021 |
| ID | 81X2600613 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Translational Research Project |
| Funding | 293688.26€ 293.688,26 |
| Begin | 2016-10-0101.10.2016 |
| End | 2021-11-3030.11.2021 |
| ID | 81X2710146 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Thomas Eschenhagen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Translational Research Project |
| Funding | 1270756.48€ 1.270.756,48 |
| Begin | 2016-09-0101.09.2016 |
| End | 2021-11-3030.11.2021 |
End-stage heart failure patients suffer from high mortality rates and have very limited treatment options. The availability of cardiomyocytes from human induced pluripotent stem cells (hiPSC) opens the possibility of allogeneic transplantation of new heart muscle mass. A recent study gives compelling evidence that transplantation of hiPSC-derived cardiomyocytes in the form of engineered heart tissue (EHT) improves cardiac function in a guinea pig myocardial infarction model. To pave the way for a first clinical trial, two critical issues will be addressed: 1) determination of the minimal effective dose/size in guinea pig and 2) translation to a large animal model (minipig myocardial infarction). Major endpoints are the therapeutic efficacy of small doses/sizes of EHTs in guinea pig myocardial infarction model, survival and growth of EHT in minipig under optimized immunosuppression and therapeutic efficacy in minipig.
| ID | 81X2600413 |
| Institution | Technische Universität München |
| Project leader | Angelika Schnieke |
| Site | München |
| Project type | Translational Research Project |
| Funding | 132507.00€ 132.507,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2600614 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Christian Kupatt |
| Site | München |
| Project type | Translational Research Project |
| Funding | 199757.00€ 199.757,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2600703 |
| Institution | Ludwig-Maximilians-Universität München |
| Project leader | Eckhard Wolf |
| Site | München |
| Project type | Translational Research Project |
| Funding | 92430.00€ 92.430,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2710148 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Lucie Carrier |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Translational Research Project |
| Funding | 22200.00€ 22.200,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-12-3131.12.2019 |
Homozygous or compound heterozygous truncating mutations in MYBPC3 encoding cardiac myosin-binding protein C (cMyBP?C) cause neonatal cardiomyopathy, which rapidly evolves into systolic heart failure and death within the first year of life. We recently provided evidence of longterm disease prevention by Mybpc3 gene therapy in homozygous Mybpc3?targeted knock?in mice, which genetically mimic human neonatal cardiomyopathies. In the absence of alternative treatment options except heart transplantation, gene therapy is a realistic treatment option for this subset of infants with severe and fatal neonatal cardiomyopathy. Our main objective towards clinical application is to reproduce our mouse findings in a larger animal model. Our gene therapy medicinal product is a recombinant adeno?associated virus serotype 9, which contains the human MYBPC3 cDNA under the control of human cardiac troponin T promoter. The project aims at the generation of a pig model of neonatal cardiomyopathy carrying bi?allelic truncating MYBPC3 mutations with the combination of CRISPR/Cas9 RNA?guide nuclease, somatic cell nuclear transfer and embryo transfer. We expect to produce bi?allelic truncating mutations that will result in a severe, fatal neonatal cardiomyopathy in pigs.
| ID | 81X2700209 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Georg Lutter |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Translational Research Project |
| Funding | 325107.48€ 325.107,48 |
| Begin | 2016-01-0101.01.2016 |
| End | 2017-12-3131.12.2017 |
The aim of this project is to develop and verify a new mitral valved stent, fully adapted to the anatomy of mitral regurgitation of diseased hearts by means of a transapical mitral-valve stent implantation in the beating heart without using a heart-lung machine. Focus of this project will be the evaluation in the mitral regurgitation animal model. The design of the stent is supposed to be further developed for the mitral position, so that a greater match with the natural anatomy is attained with a new oval shape. In addition to the apical fixation, another fixation system shall also be developed. The additional anchorage shall ensure the correct anatomical position of the stent.
| ID | 81X2600242 |
| Institution | Klinikum der Universität München |
| Project leader | Oliver Söhnlein |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2800164 |
| Institution | Westfälische Wilhelms-Universität Münster |
| Project leader | Alexander Zarbock |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2800156 |
| Institution | Technische Universität Dresden |
| Project leader | Triantafyllos Chavakis |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-09-0101.09.2016 |
| End | 2018-08-3131.08.2018 |
| ID | 81X2600238 |
| Institution | Klinikum der Universität München |
| Project leader | Oliver Söhnlein |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-09-0101.09.2016 |
| End | 2018-06-3030.06.2018 |
| ID | 81X2710149 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Christian Meyer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-01-3131.01.2019 |
| ID | 81X2800159 |
| Institution | Heinrich-Heine-Universität Düsseldorf |
| Project leader | Nikolaj Klöcker |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14163.60€ 14.163,60 |
| Begin | 2016-10-0101.10.2016 |
| End | 2019-01-3131.01.2019 |
| ID | 81X2800168 |
| Institution | Universitätsklinikum Ulm |
| Project leader | Michael Kühl |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-02-0101.02.2017 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2600619 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Karl-Ludwig Laugwitz |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-01-3131.01.2018 |
| ID | 81X2600618 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Project leader | Alessandra Moretti |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800167 |
| Institution | Philipps-Universität Marburg |
| Project leader | Robert Grosse |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14985.49€ 14.985,49 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200133 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Cooperation with External Partners |
| Funding | 5998.42€ 5.998,42 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800146 |
| Institution | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (MPG) |
| Project leader | Friedemann Kiefer |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600517 |
| Institution | Deutsches Herzzentrum München |
| Project leader | Heribert Schunkert |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 4808.45€ 4.808,45 |
| Begin | 2017-03-0101.03.2017 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2800170 |
| Institution | Justus-Liebig-Universität Gießen |
| Project leader | Norbert Weißmann |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 23000.00€ 23.000,00 |
| Begin | 2017-03-0101.03.2017 |
| End | 2019-12-3131.12.2019 |
| ID | 81X2600244 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-04-3030.04.2018 |
| ID | 81X2800169 |
| Institution | Universitätsklinikum Aachen |
| Project leader | Joachim Jankowski |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-04-3030.04.2018 |
| ID | 81X2300157 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Thomas Meyer |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 9649.93€ 9.649,93 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-09-3030.09.2018 |
| ID | 81X2800160 |
| Institution | Philipps-Universität Marburg |
| Project leader | Ralph T. Schwarz |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10738.58€ 10.738,58 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-09-3030.09.2018 |
| ID | 81X2710153 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Bärbel Ulmer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 15881.54€ 15.881,54 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800163 |
| Institution | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
| Project leader | Ole Pleß |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 19000.00€ 19.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800166 |
| Institution | Philipps-Universität Marburg |
| Project leader | Volker Ruppert |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 38806.00€ 38.806,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-09-3030.09.2018 |
| ID | 81X2300166 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Thomas Meyer |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 32215.17€ 32.215,17 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-09-3030.09.2018 |
| ID | 81X2500156 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Christoph Dieterich |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 31938.76€ 31.938,76 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800165 |
| Institution | Universität zu Köln |
| Project leader | Leo Kurian |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 31939.46€ 31.939,46 |
| Begin | 2017-01-0101.01.2017 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2500204 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Martin Borggrefe |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 9604.98€ 9.604,98 |
| Begin | 2016-09-0101.09.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2800157 |
| Institution | Westfälische Wilhelms-Universität Münster |
| Project leader | Eric Schulze-Bahr |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 39667.85€ 39.667,85 |
| Begin | 2016-11-0101.11.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600232 |
| Institution | Klinikum der Universität München |
| Project leader | Stefan Kääb |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 9934.00€ 9.934,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2019-07-3131.07.2019 |
| ID | 81X2800145 |
| Institution | Universitätsklinikum Regensburg |
| Project leader | Lars Maier |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10175.82€ 10.175,82 |
| Begin | 2016-04-0101.04.2016 |
| End | 2019-07-3131.07.2019 |
| ID | 81X2600411 |
| Institution | Technische Universität München |
| Project leader | Stefan Engelhardt |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2800147 |
| Institution | Universitätsklinikum Regensburg |
| Project leader | Gunter Meister |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-03-0101.03.2016 |
| End | 2017-09-3030.09.2017 |
| ID | 81X2500205 |
| Institution | Ruprecht-Karls-Universität Heidelberg |
| Project leader | Thomas Wieland |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 18500.00€ 18.500,00 |
| Begin | 2016-10-0101.10.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2700210 |
| Institution | Universitätsklinikum Schleswig-Holstein |
| Project leader | Hans-Heiner Kramer |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 25000.00€ 25.000,00 |
| Begin | 2016-09-0101.09.2016 |
| End | 2017-08-3131.08.2017 |
| ID | 81X2800161 |
| Institution | Universitätsklinikum Essen |
| Project leader | Dobromir Dobrev |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 18500.00€ 18.500,00 |
| Begin | 2016-09-0101.09.2016 |
| End | 2017-08-3131.08.2017 |
| ID | 81X2800158 |
| Institution | Krankenhausbetriebsgesellschaft Bad Oeynhausen mbH |
| Project leader | Hendrik Milting |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 25000.00€ 25.000,00 |
| Begin | 2016-08-0101.08.2016 |
| End | 2017-07-3131.07.2017 |
| ID | 81X2600234 |
| Institution | Klinikum der Universität München |
| Project leader | Stefan Kääb |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 9681.00€ 9.681,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2019-07-3131.07.2019 |
| ID | 81X2800150 |
| Institution | Universitätsklinikum Regensburg |
| Project leader | Lars Maier |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10675.00€ 10.675,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2019-07-3131.07.2019 |
| ID | 81X2800154 |
| Institution | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| Project leader | Susanne Wurm |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 22824.64€ 22.824,64 |
| Begin | 2016-05-0101.05.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2400127 |
| Institution | Universitätsmedizin Greifswald |
| Project leader | Sabina Ulbricht |
| Site | Greifswald |
| Project type | Cooperation with External Partners |
| Funding | 18785.56€ 18.785,56 |
| Begin | 2016-05-0101.05.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2600236 |
| Institution | Klinikum der Universität München |
| Project leader | Oliver Söhnlein |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 9999.81€ 9.999,81 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2800152 |
| Institution | Universitätsklinikum Aachen |
| Project leader | Twan Lammers |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-06-3030.06.2017 |
| ID | 81X2100235 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Sophie Van Linthout |
| Site | Berlin |
| Project type | Cooperation with External Partners |
| Funding | 9445.06€ 9.445,06 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-03-3131.03.2018 |
| ID | 81X2800143 |
| Institution | Technische Universität Berlin |
| Project leader | Jens Kurreck |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 14000.00€ 14.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-03-3131.03.2018 |
| ID | 81X2500148 |
| Institution | Universitätsklinikum Heidelberg |
| Project leader | Marc Freichel |
| Site | Heidelberg/Mannheim |
| Project type | Cooperation with External Partners |
| Funding | 17500.00€ 17.500,00 |
| Begin | 2016-03-0101.03.2016 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2800142 |
| Institution | Universität des Saarlandes |
| Project leader | Peter Lipp |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 20500.00€ 20.500,00 |
| Begin | 2016-03-0101.03.2016 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2800155 |
| Institution | Justus-Liebig-Universität Gießen |
| Project leader | Klaus-Dieter Schlüter |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 11962.48€ 11.962,48 |
| Begin | 2016-06-0101.06.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200201 |
| Institution | Kerckhoff-Klinik, Gesellschaft mit beschränkter Haftung |
| Project leader | Christian Hamm |
| Site | RheinMain |
| Project type | Cooperation with External Partners |
| Funding | 8000.00€ 8.000,00 |
| Begin | 2016-06-0101.06.2016 |
| End | 2017-12-3131.12.2017 |
| ID | 81X2200134 |
| Institution | Johann Wolfgang Goethe-Universität Frankfurt am Main |
| Project leader | Andreas Zeiher |
| Site | RheinMain |
| Project type | Cooperation with External Partners |
| Funding | 4000.00€ 4.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2800148 |
| Institution | Medizinische Hochschule Hannover |
| Project leader | Thomas Thum |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 16000.00€ 16.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2017-05-3131.05.2017 |
| ID | 81X2300162 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Rolf Wachter |
| Site | Göttingen |
| Project type | Cooperation with External Partners |
| Funding | 7950.00€ 7.950,00 |
| Begin | 2016-12-0101.12.2016 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2800149 |
| Institution | Medizinische Hochschule Hannover |
| Project leader | Sandor Batkai |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10426.00€ 10.426,00 |
| Begin | 2016-03-0101.03.2016 |
| End | 2017-02-2828.02.2017 |
| ID | 81X2600701 |
| Institution | Ludwig-Maximilians-Universität München |
| Project leader | Thomas Gudermann |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 14988.78€ 14.988,78 |
| Begin | 2016-04-0101.04.2016 |
| End | 2018-10-0101.10.2018 |
| ID | 81X2800144 |
| Institution | Universität Regensburg |
| Project leader | Armin Kurtz |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2016-01-0101.01.2016 |
| End | 2018-10-0101.10.2018 |
| ID | 81X2710143 |
| Institution | Universitätsklinikum Hamburg-Eppendorf |
| Project leader | Thomas Eschenhagen |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Cooperation with External Partners |
| Funding | 2700.00€ 2.700,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2016-11-3030.11.2016 |
| ID | 81X2600235 |
| Institution | Klinikum der Universität München |
| Project leader | Christian Weber |
| Site | München |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2016-11-3030.11.2016 |
| ID | 81X2800151 |
| Institution | Universitätsklinikum Aachen |
| Project leader | Heidi Noels |
| Site | Extern |
| Project type | Cooperation with External Partners |
| Funding | 10000.00€ 10.000,00 |
| Begin | 2016-04-0101.04.2016 |
| End | 2016-11-3030.11.2016 |
| ID | 81X2100135 |
| Institution | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
| Project leader | Michael Bader |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 001) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2700125 |
| Institution | Universität zu Lübeck |
| Project leader | Zouhair Aherrahrou |
| Site | Hamburg/Kiel/Lübeck |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 001) |
| Funding | 15000.00€ 15.000,00 |
| Begin | 2017-01-0101.01.2017 |
| End | 2018-12-3131.12.2018 |
| ID | 81X2100251 |
| Institution | Charité - Universitätsmedizin Berlin |
| Project leader | Karl Georg Häusler |
| Site | Berlin |
| Project type | Shared Expertise (SE) | SE Trait | SE provider (SE 159) |
| Funding | 38750.10€ 38.750,10 |
| Begin | 2017-03-0101.03.2017 |
| End | 2020-06-3030.06.2020 |
| ID | 81X2300168 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Project leader | Rolf Wachter |
| Site | Göttingen |
| Project type | Shared Expertise (SE) | SE Trait | SE user (SE 159) |
| Funding | 45796.00€ 45.796,00 |
| Begin | 2017-03-0101.03.2017 |
| End |